1 
      
UMCC Protocol #: UMCC 2013.117 Amendment 5: 8/9/2016 
 
  TITLE:   A Randomized Phase II Study of Androgen Deprivation Therapy w ith or without 
Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostat e Cancer.  
   Coordinating Center:   The University of Michigan 
  Overall Study Principal Inves tigator (PI) and IND Sponsor: 
 
Maha Hussain, MD, FACP, FASCO Division of Hematology Oncology Northwestern Medicine 676 N. St. Clair, Suite 850 Chicago, Illinois 60611 Phone: 312-695-6180 Fax: 312-695-4530 E-mail: maha.hussain@northwestern.edu 
  
  
2 
 Site Specific and Other Co-Investigators: 
Site Investigator 
Phillip Palmbos, M.D. Ph.D. 
NCRC Bldg 520, Room 1342  
1600 Huron Parkway 
Ann Arbor, MI 48109-2800 Phone: 734-763-0953 
Fax: 734-647-6977  
Email: ppalmbos@umich.edu  
 Translational Co-Investigator 
Felix Feng, M.D. 
Department of Radiation Oncology  
University of Californi a at San Francisco 
1825 4th Street, First Floor, Rm M2267 
San Francisco, CA 94143  
Email: felix.feng@ucsf.edu  
Site Investigator 
Wm. Kevin Kelly, DO 
Thomas Jefferson University 
1025 Walnut Street 
College Building, Suite 700 Philadelphia, PA 19107 
Telephone: 215-503-5455 
E-mail:
 wm.kevin.kelly@jefferson.edu  
  Translational Co-Investigator 
Karen E. Knudsen, PhD 
Thomas Jefferson University 
233 S. 10th St., Rm 1008 
Philadelphia, PA 19107 Telephone: 215-503-7595 
E-mail: Karen.Knudsen@jefferson.edu 
 
Site Investigator 
Alicia K. Morgans, MD 
Vanderbilt-Ingram Cancer Center 2220 Pierce Ave. 
777 PRB 
Nashville, TN 37232 Telephone: 615-322-4967  
Fax: 615-343-7602 
Email: alicia.morgans@vanderbilt.edu  
 
 Site Investigator 
Dr. Vivek K. Arora 
Washington University in St. Louis Asst Prof of Medicine 
Int Med – Medical Oncology 
660 S. Euclid Ave. CB 8056 St. Louis, MO 63110 
Telephone: 314-286-1906 
Fax: 314-362-7086 Email: varora@dom.wustl.edu  
Site Investigator 
Neeraj Agarwal, MD 
Assistant Professo r of Medicine, 
Huntsman Cancer Institute, University of Utah. 
2000 Circle of Hope, Ste 2123, 
Salt Lake City, Utah 84112 
Telephone: 801-585-9682 Fax: 801-585-0124 
Email: Neeraj.Agarwal@hci.utah.edu  
 Site Investigator 
Emmanuel Antonarakis, M.D 
Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins Orleans Street, Rm 1M45 
The Bunting-Blaustein Cancer 
Research Building Baltimore, MD 21231 
Telephone: 410-502-7528 
Email: eantona1@jhmi.edu  
 
Site Investigator 
Przemyslaw Twardowski, M.D. 
City of Hope Cancer Center 1500 E. Duarte Road 
Duarte, CA 91010 
Telephone: 626-256-4673 ext 68218 Fax: 626-301-8898 
Email: ptwardowski@coh.org  
 Site Investigator 
Benedito Carneiro, MD 
Northwestern University 233 East Superior Street  
Olson Pavilion, 1st floor  
Chicago, IL 60611 Telephone: 312-472-1234 
Fax: 312-472-0564 
Email: benedito.carneiro@northwestern.edu    
3 
 Radiology Co-Investigator  
Jon A. Jacobson, M.D. 
University of Michigan 
Taubman Center, Room 2910L 
1500 East Medical Center Dr., SPC 5326 Ann Arbor, MI 48109 
Phone: 734-936-4365 
Fax: 734-936-9723 E-mail: jjacobsn@umich.edu  
 Radiology Co-Investigator   
Matthew S. Davenport, M.D. 
University of Michigan 
1500 East Medical Center Dr. 
Ann Arbor, MI 48109 Telephone: 734-936-4566 
Fax: 734-764-4230 
E-mail: matdaven@med.umich.edu  
 
Radiology Co-Investigator Corrie Yablon, M.D. 
University of Michigan 
Taubman Center, Room 2910Q 
1500 East Medical Center Dr., SPC 5326 
Ann Arbor, MI 48109 
Phone: 734-
 232-9402 
E-mail; cyablon@umich.edu 
 Radiology Co-Investigator Elaine Caoili, M.D. 
University of Michigan 
Taubman Center, Room B1D502 
1500 East Medical Center Dr., SPC 5030 
Ann Arbor, MI 48109 
Phone: 734-936-4460 E-mail: caoili@umich.edu  
 
Biostatistician 
Stephanie Daignault-Newton, M.S. 
2180 SPHII 
1415 Washington Heights 
Ann Arbor, MI, 48109-0473 Telephone: 734-647-3271 
Email: sfaruzzi@umich.edu 
 Study Pathologist 
Scott Tomlins, M.D. 
University of Michigan Hospital 
1500 E. Medical Center Drive 
2G332 University Hospital, SPC 5054 Ann Arbor, MI 48109-5054 
Telephone: 734-763-8261 
 Email:
 tomlinss@med.umich.edu  
 
 
Administrative Personnel 
University of Michigan Multi-Site Coordinator 
Kathleen Granlund, CCRP 
Cancer Center Clinical Trials Office 
North Campus Research Complex (NCRC) Building 300  Main 
Ann Arbor, MI 48109-2800 
Telephone: 734-936-0563 Fax: 734-232-0744 
Email: kemarsh@med.umich.edu  
 
Ben Wright, CAPM CCRP 
Cancer Center Clinical Trials Office 
North Campus Research Complex (NCRC) Building 300  Main 
Ann Arbor, MI 48109-2800 
Telephone: 734-763-0722 Fax: 734-232-0744 
Email: bdwright@med.umich.edu  
 Technical Director, Mi chigan Center for 
Translational Pathology 
Javed Siddiqui, MS, MT(ASCP, CLsp (MB)) 
Room 1138  2900 Huron Parkway Suite 100 
Ann Arbor, MI 48105 
Telephone (734) 232-0829; Fax (734) 232-0805 Email:
 siddiqui@med.umich.edu  
 
   
Pfizer Supplied Agent  Palbociclib (Ibrance®) 
 
4 
 UMCC Protocol #: UMCC 2013.117 
Amendment 5: 8/9/2016  TITLE:  A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-Positive Metas tatic Hormone-Sensitive Prostat e Cancer. 
 Site Principal Investigator Protocol Signature Page  The signature below constitutes the approval of this protocol and the attachments, and provides the necessary assurances that this study will be conducted according to all stipulations of the protocol, inc luding all statements regardin g confidentiality, and 
according to local legal and regul atory requirements and applic able US federal regulations 
and ICH guidelines.    Printed Name: ____________________________________________ 
  Signature:________________________________________________ 
  Date:____________________ 
   
5 
  
STUDY SCHEMA 
 
          
Registration  
Biopsy of Metastatic Lesion  
Arm 1: ADT alone, n=20 Arm 2: ADT + Palbociclib, N=40 RB Positive (n=60 )RB negative- 
Off Protocol New M1 Prostate Cancer 
6 
 TABLE OF CONTENTS  
 Page 
PI PROTOCOL SIGNATURE PAGE ...................................................................................4 
SCHEMA  ..................................................................................................................................5 
1.  OBJECTIVES  .....................................................................................................................9 
 1.1 Primary Objectives  ......................................................................................................9 
 1.2 Secondary Objectives  ..................................................................................................9 
 1.3 Correlative Objectives  .................................................................................................9 
 2.  BACKGROUND  ...............................................................................................................10 
     2.1 Metastatic Prostate Cancer and Androgen Signaling .............................................10      2.2 Role RB in Metastatic Prostate Cancer ....................................................................10      2.3 Role of CDK4/6 Inhibitors in Prostate Cancer  
………………..........................................................................................…………………....10      2.4 Palbociclib …………………………………………… ........................……………...12 
     2.5 Rationale for Combination of Palbociclib and ADT ............…… .…………….....16      2.6 Correlative Studies Background and Rationale .....………………… …………….17 
 3.  DRUG INFORMATION  ..................................................................................................19 
     3.1 Palbociclib (PD 0332991) ........................................................................................... 19      3.2 Bicalutamide (Casodex®)  ...........................................................................................28 
     3.3 Goserelin acetate implant (Zoladex®)  .....................................................................29 
     3.4 Leuprolide (Lupron Depot®)  .....................................................................................32 
 
4.  PATIENT SELECTION  ..................................................................................................35 
 4.1 Inclusion Criteria   ............................................................. .........................................35 
 4.2 Exclusion Criteria  ......................................................................................................37 
 4.3 Inclusion of Women and Minorities  .........................................................................38 
 
5. REGISTRATION  ........................................................................................................38 
     5.1 Pretreatment Evaluation  
...........................................................................................38 
     5.2 Subject Screening and Registration Procedure  ......................................................38 
     5.3 Biopsy and Randomization ……………………………… ………………………..40 
     5.4 Data Management   ............................................................. ........................................41 
 
6.  STRATIFICATION, RANDOMI ZATION AND TREATMENT PLAN ....................41 
 6.1 Stratification and Randomization ............................................................................41 
 6.2 Agent Administration  ................................................................................................42 
     6.3 General Concomitant Medicatio n and Supportive Care Guidelines  ....................43 
 6.4 Duration of Therapy  ..................................................................................................44 
 6.5 Duration of Follow Up  ...............................................................................................45 
 7.  DOSING DELAYS/DOSE MODIFICATIONS  .............................................................45 
      7.1 Palbociclib Dose Reductions …………..…………………………… ……………46 
      7.2 Bicalutamide Dose Hold                 48 
 8.  ADVERSE EVENTS:  LIST A ND REPORTING REQUIREMENTS  .......................49 
7 
      8.1 Adverse Events and Potential Risks Related to Palbociclib  ....................................49 
     8.2 Adverse Event Reporting Requirements  ..................................................................49 
     8.3 Definitions  ....................................................................................................................50 
     8.4 Adverse Event Characteristics  ...................................................................................52 
     8.5 Serious Adverse Event Reporting Guidelines  ..........................................................52 
     8.6 Serious Adverse Event Reporting to the FDA  ..........................................................54 
      
9.  TISSUE PROCESSING/CORRELATIVE/SPECIAL STUDIES  ................................54 
9.1 Tissue/Laboratory Correlative Studies  ....................................................................54 
9.2 Description of RB Assessment and Correlative Studies  .........................................60 
 10.  STUDY CALENDAR  .....................................................................................................63 
 11.  MEASUREMENT OF EFFECT  ...................................................................................64 
11.1 Definitions  .................................................................................................................64 
11.2 Response and Progression Criteria  ........................................................................65 
11.3 Methods for Evaluation of Measurable Disease  ....................................................67 
11.4 Progression-Free Survival  .......................................................................................68 
11.5 Evaluation of Best Overall Response  .....................................................................68 
11.6 Duration of Response  ...............................................................................................69 
 12.  DATA MANAGEMENT AND MONITORING  ..........................................................70 
      12.1 Data and Safety Monitoring Procedures …………………… ......……………….70 
      12.2 Clinical Monitoring Procedures ……………………………… ......……………...70 
      12.3 Quality Assurance and Audits ………………………………… ......……………..72 
 
13.  STATISTICAL CONSIDERATIONS  ..........................................................................72 
 13.1 Statistical Design  ......................................................................................................72 
 13.2 Analysis Plan  ............................................................................................................73 
 13.3 Correlative Endpoints Analysis  ..............................................................................73 
 
REFERENCES  .......................................................................................................................75 
 APPENDICES 
APPENDIX A  
Performance Status Criteria ........................................................................................78 
APPENDIX B  
 
[Standard Operating Procedure (S OP) for Biopsy of Metastatic P rostate Cancer Lesion 
  In Bone……………………………………………………………… .....……………….79 
APPENDIX C 
Standard Operating Procedure (SOP) for Biopsy of Metastatic Pro state Cancer Lesion in 
Soft Tissue……………………………………………………………………………….80 
APPENDIX D  
Standard Operating Procedure (SOP) for Handling Samples ....... .............................81 
APPENDIX E  
Standard Operating Procedure (S OP) for Shipping of non-CTC Clin ical Samples ...83 
APPENDIX F 
8 
 Standard Operating Procedure (S OP) for Shipping of CTC Clinical  Samples ..................86 
APPENDIX G  
Patient Medication Diary- Palbociclib .......................................................................88 
APPENDIX H  
Patient Medication Diary- Bicalutamide ....................................................................89 
 
  
9 
 1. OBJECTIVES  
 
1.1  Primary Objectives 
 
1.1.1 To compare the rate of PSA < 4ng/mL after 28weeks of protocol t reatment between 
RB-positive patients with metastatic hormone-sensitive prostate  cancer randomized 
to combined androgen deprivation (CAD: LHRH agonist + bicalutam ide) versus 
those randomized to CAD + palbociclib.  
 
1.2  Secondary Objectives 
 
1.2.1 To assess the safety and tolerability of the combination of CAD + palbociclib. 
1.2.2 To assess the rate of undetectable PSA (<0.2ng/mL). 
1.2.3 To assess biochemical and clin ical progression-free survi val. 
1.2.4 To assess PSA and radiographic response rates.   
 
1.3  Correlative Objectives  
 
1.3.1 To determine whether cyclin D1, cyclin D1B, p16, CDK4, E2 F1, Cyclin A, MCM7, 
or Ki67 levels in pretreatment metastatic tumor biopsy tissue p redict a subset of 
tumors responsive to palbocicli b or overall response rates. 
 
1.3.2   To evaluate tumor transcriptome and mutational signatur es to identify biomarkers 
which predict response to palbociclib. 
  1.3.3 To create a tissue repository consisting of hormone-sensi tive metastatic prostate 
cancer specimens with associated R B status and cli nical data wh ich can be used to 
correlate RB status with general clinical outcomes and explore and validate 
important genes identified in 1.3.2. 
 1.3.4 To assess if the number of circulating tumor cells (CTCs)  is associated with 
response to therapy when collected at pre-treatment, week 12, a fter 28 weeks of 
therapy, and at progression/or c oming off protocol treatment. 
 1.3.5 To assess if CTC heterogeneity , as assessed by the relati ve distribution of CTC 
phenotypes, predicts either r esponse to palbociclib or overall response rates. 
  
10 
 2. BACKGROUND  
 
2.1  Metastatic  Prostate Cancer and Androgen Signaling  
Every year in the United States, about 30,000  men die of metas tatic prostate cancer (PCa).1 Since 
the introduction of orchiectomy as the first androgen deprivati on therapy (ADT) over seventy years 
ago,2 progress in developing new treatments for patients with metast atic hormone-sensitive 
prostate cancer (mHSPC) has been limited to introducing different modalities of delivering ADT.3  
 
The primary therapeutic maneuver for newly diagnosed metastatic  prostate cancer is androgen 
deprivation, which is accomplishe d by surgical castration or co mbined androgen deprivation 
therapy using LHRH-agonists/anta gonists with or without an anti androgen such as bicalutamide. 
Although the vast majority of mHSPC will initially respond to A DT, it is well established that the 
quality and duration of response is variable, and most will pro gress to castration-resistant disease.  
The current median survival of mHSPC is about 4 years.4 At present, all patients with newly 
diagnosed mHSPC are treated with a “one size fits all” approach with no means by which to select appropriate therapeutic regimens based on tumor profiling.    
2.2  Role of RB in Metastatic Prostate Cancer  
Androgens drive proliferation of prostate cancer cells both in initial disease and even after 
progression to castration-resistance. An important mechanism by which androgens drive 
proliferation is up-regulation of cyclin D which complexes with the cyclin-dependent kinase 
(CDK) 4/6, resulting in phosphorylation of RB, a cell-cycle bra ke. Because RB is a transcriptional 
repressor which binds to the regulatory region of genes whose f unctions are important for cell 
cycle progression and DNA replication, phosphorylation of RB re lieves this repression and allows 
the cell to proceed through the cell-cycle and divide. RB is th erefore an important tumor suppressor 
and is lost in early stages in  several human malignancies (e.g. breast, cervical, and small cell lung 
cancer).
5,6 Because AR signaling is able to inactivate this cell-cycle brake, most early stage prostate 
cancers retain wild-type RB function, and pertur bations in this  pathway (loss of RB, upregulation 
of cyclin D) are instead felt t o promote castra tion-resistance.7   
 The relationship between AR and RB is complex.  While AR signaling results in RB phosphorylation and cell-cycle p rogression, expression of the gene encoding the androgen receptor 
(AR) is also under RB control.
8 Loss of RB caused de-repression of the AR locus, excessive AR 
production, and castration-resistan t (ligand-independent) AR ac tivity that proved sufficient to 
bypass hormone therapy.8 Therefore, AR signaling is closely linked with RB control. 
 
2.3  Role of CDK4/6 Inhibitors in Prostate Cancer    
 
CDK4/6 inhibition markedly inhib its prostate cancer growth in vitro and in vivo.  
Exposure of hormone-sensitive prostate cancer cell lines to the  CDK4/6 inhibitor, palbociclib (PD 
0332991) significantly decreases active cell cycle progression (through measurement of BrdU 
incorporation kinetics) (Figure 1, top left) and production of factors (cyclins A and E1) necessary 
for cell cycle progression in an RB-dependent manner (Figure 1,  top right). These results were 
recapitulated in studies examini ng human xenograft cultures (Fi gure 1, bottom) as well as ex vivo  
human tissue model systems. Such decreases in cell cycle progre ssion were accompanied by 
significant decreases in the clin ical tumor proliferation marke r Ki67 (Figure 2).9 
11 
  
RB-proficient prostate cancer c ells are preferentially sensitiv e to CDK4/6 inhibition.  

12 
 Studies utilizing matched RB-knockdown and control populations have demonstrated a clear 
requirement for the retention of  functional RB protein in the r esponse to CDK4/6 inhibition.  
Among populations deficient for RB protein, inhibition of CDK4/ 6 activity was not able to 
decrease the rate of cells progressing through active cell cycl e.9 
 
CDK4/6 inhibitors suppress AR function.  
Previous studies have demonstrated that CDK4/6 directly associa tes with the androgen receptor 
and enhances transcriptional activity in prostate cancer cells.10 AR activity is coupled to the cell 
cycle machinery primarily through its ability to up-regulate cyclin D protein level (reviewed in8). 
Once produced, cyclin D partners with CDKs 4 and 6, and phosphorylates RB protein, functionally inactivating the protein and ultimately relieving the transcrip tional repression elicited by RB. This 
results in increased E2F-mediated gene transcription and produc tion of factors that are required 
for cells to progress through the cell cycle and in to S-phase.   I n  t h i s  c o n t e x t ,  t h e  e f f e c t  o f  
palbociclib administration is sta bilization of cyc lin D protein  levels.
11  Results from the Knudsen 
laboratory and others have shown that cyclin D protein is capable of negatively regulating AR activity at AR target genes.
12  Thus, increases in intracellular cyclin D protein levels are known to 
negatively regulate AR function, and would be hypothesized to d ecrease AR-driven prostate 
cancer cell growth.  This postulate is supported by recent, unp ublished microarray analyses of AR-
positive prostate cancer cells in the presence and absence of PD 0332991 (Karen Knudsen, personal communication).  palboc iclib selectively suppressed ex pression of a subset of AR target 
genes known to be critical for castrate-resistant AR activity ( eg UBE2C, Rad51, Fen1), while 
having no effect on early-stage AR targets (e.g. PSA, not shown ), and little impact on others such 
as Nkx3.1.  Therefore, because palbociclib suppressed AR-depend ent gene expression of some 
targets, it may act in concert with standard-of-care (androgen deprivation) to further suppress 
expression of target genes known to promote disease progression/therapeutic response.  
 
2.4  Palbociclib  
 
 Palbociclib is a highly selective reversible inhibitor of CDK 4 and 6 currently bei ng evaluated as 
an anti-cancer therapy and approved for the treatment of metast atic breast cancer.
13  Palbociclib 
specifically inhibits CDK4-catal yzed phosphorylation of retinob lastoma protein.  It has previously 
been shown to inhibit growth of human xenograft tumors includin g prostate cancers grown in 
mice.9   
 
Mechanism of Action 
 
Selectivity:  Palbociclib is a highly selective inhibitor of CD K4/cyclinD1 kinase activity (IC50 = 
11 nM; Ki = 2 nM). Palbociclib ha s selectivity for CDK4/6, with  little or no activity against a large 
panel of 34 other protein kina ses including other CDKs and a wi d e  v a r i e t y  o f  t y r o s i n e  a n d  
serine/threonine kinases. CDK6, an other enzyme that also comple xes with cyclin-D subunits, is 
also commonly expressed in mam malian cells and tumors. CDK6 is highly homologous to CDK4 
and can perform the same function by phosphorylating RB, thus p otentially creating a redundant 
mechanism to promote cell cycle progression. Consequently, inhi bition of both enzymes is 
necessary to ensure complete suppression of RB phosphorylation and the greatest possible 
spectrum of antitumor activity. Results indicate that palbocicl ib inhibits CDK6 with equivalent 
potency to CDK4. 
 
13 
 Inhibition of RB phosphorylation:  The only known natural subst rate for CDK4/cyclinD1 is the 
retinoblastoma gene product, RB. Specific CDK4 phosphorylation sites on RB include serine-780 
and serine-795. Therefore, the phosphorylation status of RB at these specific sites in treated tumors 
can serve as an appropriate biomarker for target modulation by palbociclib. The IC50 for reduction 
of RB phosphorylation at serine-780 in the MDA-MB-435 breast ca rcinoma cell line was 0.066 
M. Palbociclib was equally effective at reducing RB phosphorylation at serine-795 in this tumor 
cell line with an IC50 of 0.063 M. Similar effects on serine-780 and serine-795 phosphorylation  
were obtained in the hormone sensi tive prostate cancer cell lin e VCaP.9 
 
Anti-Proliferative Effects:  Palbociclib inhibits cellular proliferation and prevents cellular DNA 
synthesis by preventing cells from entering S phase of the cell  cycle. Palbociclib inhibited 
thymidine incorporation into the DNA of a panel of RB-positive human breast, colon, lung and 
prostate cancers. Palbociclib wa s also effective in preventing cell cycle progre ssion in human 
leukemias and in nontransformed human epithelial cells and fibr oblasts and was equally effective 
in suppressing cell division in human tumor cell lines. 
 
A selective CDK4/cyclinD inhibitor should cause a specific accu mulation of cells in G1, but have 
no effect on other phases of the cell cycle, in which cells sho uld continue to progress and eventually 
decline in number. MDA-MB-453 br east carcinoma cells that were exposed to various 
concentrations of palbociclib for 24 hours show a  significant i ncrease in the percentage of cells in 
G1 in the presence of as little as 0.04 M palbociclib with a concomitant decline in other phases 
of the cell cycle. Similar resu lts were obtained in panels of p rostate cancer cell lines.9 
 
Finally, to provide further evi dence of the selectivity of palb ociclib, the compound was tested 
against RB-negative tumor cells, which should not be sensitive to a specific CDK4 inhibitor.  
Palbociclib was tested against the MDA-MB-468 human breast carc inoma and the H2009 human 
non-small cell lung carcinoma, both of which have deleted RB. The compound had no anti-
proliferative activity on the se cells when assayed at 3 M (highest concentration tested), which is 
1 to 2 orders of magnitude higher than the concentration necess ary to inhibit RB-positive tumor 
cells. 
 
Nonclinical Activity 
 
The MTD in SCID mice was 150 mg/kg/day when administered orally , once a day, for 14 days. 
The MTD was defined as the highe st dose that was nonlethal (<LD 10). At the MTD on this 
regimen, palbociclib has significant antitumor efficacy against  multiple human tumor xenograft 
models (including the PC-3 prostate cancer cell line). The Colo-205 model is exquisitely sensitive 
to palbociclib. At doses as low as 12.5 mg/kg, a 13-day growth delay was obtained, indicating a 
90% inhibition of tumor growth ra te. Further evidence that the anti-tumor activity observed in RB-
positive tumors is due to inhibition of CDK4/CDK6 protein kinas e activity was obtained by testing 
palbociclib in the MDA-MB-468 breast carcinoma and the DU-145 p rostate tumor models. These 
are RB-negative tumors; and neither responded to this compound. The lack of efficacy in RB-negative tumors is consistent with the lack of anti-proliferati ve activity observed in vitro. Taken 
together, these results support the proposed mechanism of palbo ciclib (inhibition of CDK4/6-
mediated RB phosphorylation) and the specificity of the compound demonstrated in enzyme activity tests. 
 
14 
  
Nonclinical Pharmacology and Toxicology 
 
Dosing Schedules:  Further studi es investigated whether continu ous daily dosing of palbociclib 
was needed for optimal efficacy. Four dosing schedules were emp loyed against the MDA-MB-
435 breast carcinoma model over 14 days of treatment, including  continuous daily, every other 
day, every third day, and 3 courses of 3 days dosing followed b y 4-day drug holidays. The design 
of this experiment was such th at the total compound administered over the 2-week period was 
identical for each treatment schedule. The results show that a similar degree of efficacy was 
attained with all schedules, implying that an intermittent regi men is feasible without compromising 
activity.  
 
Inhibition of RB Phosphorylation:   To determine if palbociclib prevented RB phosphorylation, 
efficacious and non-efficacious doses  of palbociclib were given to mice bearing the MDA-MB-
435 breast carcinoma and the phosphorylation status of serine-780 on RB in tumor tissue was monitored over time. The results show that while all doses caus ed a reduction in the biomarker 
shortly after drug administrati on, phosphorylation returned at the non-efficacious  doses (12.5 and 
37.5 mg/kg) over the 24-hour interval before the next dose. How ever, the highly efficacious dose 
of 150 mg/kg suppressed RB seri ne-780 phosphorylation during th e full 24-hour period. These 
data suggest that complete suppr ession of RB phosphorylation ne eds to be maintained between 
drug doses to achieve significant efficacy against this particu lar tumor model.  
 
Similar experiments with the Colo-205 colon carcinoma xenograft s, which are exquisitely 
sensitive to palbociclib, shows that complete suppression of RB  phosphorylation between doses 
was found to be unnecessary for producing growth inhibition. However, for maximal effects against Colo-205 tumors (i.e., r egression), total inhibition ha d to be maintained.  
 
Comparing results of the efficacy experiments between the highl y sensitive colon tumor and the 
moderately sensitive breast tumor reveals a 7 to 8-fold differe nce in the dose necessary to produce 
comparable efficacy. The pharmacodynamic results show a similar  difference between the 2 
tumors in dose requirements necessary to suppress serine-780 ph osphorylation on RB, indicating 
that efficacy correlates with modulation of this biomarker. Ki- 67, a common marker of cell 
proliferation, was monitored in xenografts by immunohistochemic al staining with the MIB-1 
antibody. MDA-MB-435 and Colo-205 xenografts were treated with an efficacious but nontoxic 
dose of palbociclib (130 mg/kg) daily for 7 and 4 days, respectively. Tumor samples were harvested at various times after the last dose and analyzed for  RB phosphorylation and Ki-67 
expression. Relative to vehicle treated controls, RB phosphoryl ation and Ki-67 expression were 
both strongly inhibited from 1 to 24 hours afte r dosing. At 48 and 72 hours af ter the last dose, RB 
phosphorylation and Ki-67 returned to control levels in MDA-MB- 435. In Colo-205, RB 
phosphorylation and Ki-67 expressi on remained partly suppressed  through 72 hours. These results 
are consistent with the anti-proliferative mechanism expected f or a specific Cdk4/6 inhibitor. They 
also provide support for the use of Ki-67 as a biomarker of cel l proliferation in conjunction with 
palbociclib. 
Clinical Investigations 
 
As of 01 Sep 2015, palbociclib ha s been investigated in 18 clinical trials and at least 7 ongoing 
trials in humans; 19 phase 1 trials (solid tumors and hematolog ic malignancy) , three phase 1/2 
15 
 trials (multiple myeloma and breast cancer) in combination with  bortezimib or letrozole and two 
phase 3 trials in breast cancer in combination with letrozole o r fulvestrant. 
 
Phase 1 Experience and MTD Determination.  74 patients with a v ariety of solid tumors were 
treated as part of the Phase 1 t rial.  41 patients received palbociclib on a 3-week on, 1-week off 
treatment schedule (3/1) with doses ranging from 25 to 150 mg o ne daily.  An additional 33 patients 
received daily treatment with 2-week on/1-week off schedule (2/1) at a similar dose range.  The MTD doses for Phase 2 investigations was determined to be 125mg  daily for the 3/1 schedule and 
200mg daily for the 2/1 schedule.  Common adverse events relate d to treatment are listed in Section 
3.1 and included fatigue, neutrope nia, nausea, diarrhea, and an emia. 
 Phase 1/2 Experience with Palbociclib in Combination with Letro zole in Women with Breast 
Cancer:  Data is available for a Phase 1/2 trial assessing the safety an d efficacy of palbociclib 125 
mg QD on Schedule 3/1 in combination with letrozole 2.5 mg QD o n a continuous regimen for the 
first-line treatment of female patients with ER-positive, HER2-negative advanced breast cancer.14 
The Phase 1 portion of the study has completed accrual with 12 patients. In the Ph ase 2 portion of 
the study, patients were randomized to receive either letrozole  2.5 mg QD alone or palbociclib 125 
mg QD on Schedule 3/1 + letrozole 2.5 mg QD. Safety data are av ailable for 95 patients who 
received the combination, which includes 12 patients from Phase 1 and 83 patients from the Phase 
2 portion of the study.   Phase 3 Experience with Palbociclib in Combination with Letrozo le in Women with Breast 
Cancer.  In this ongoing study 666 patients were randomized in a double-blind, placebo-controlled 
trial to receive either palbociclib 125mg QD (Schedule 3/1) + l etrozole or letrozole alone. The 
most common treatment related a dverse events were neutropenia ( 41.6%), fatigue (28.5%), nausea 
(26.3%), arthralgia (22.5 %), and hot flush (21.3%). 
 Phase 3 Experience with Palbociclib in Combination with Fulvest rant in Women with Breast 
Cancer Whose Disease Progressed after Prior Endocrine Therapy.  This is an ongoing, multicenter, 
randomized, double-blind, placebo-controlled trial comparing pa lbociclib to placebo in 
combination with fluvestrant with or without goserelin for wome n whose disease has progressed 
after prior endocrine therapy.  T he most common adverse events were neutropenia (39.5%), fatigue 
(33.5%) and nausea (27.5%). 
 
Efficacy:    Results are available from 4 completed studies.  In the Phase 1 trial, stable disease 
was observed for patients with liposarcoma, testicular, kidney,  ovarian, breast, appendiceal, 
peritoneal, melanoma, thymoma and lung.  One patient had a part ial response (testicular).   
 
Final efficacy results from the Phase 2 portion of the palbocic lib/letrozole study demonstrated that 
PFS was significantly longer in the palbociclib plus letrozole arm than in the letrozole alone arm 
(20.2 months vs 10.2 months, respectively with a hazard ratio o f 0.488 (95% CI: 0.319-0.748) in 
favor of palbociclib plus letrozole (p=0.0004)).  Palbociclib p lus letrozole was also associated with 
higher objective response rates and higher clinical benefit. Th e efficacy data from palbociclib trials 
led to its FDA approval for use in metastatic breast cancer wit h letrozole. 
 
2.5  Rationale for Combination of Palbociclib and ADT in Patien ts with RB-intact 
Hormone-Sensitive Metastatic Prostate Cancer  
16 
  
Androgens drive proliferation of prostate cancer cells 
via up regulation of cyclin D which complexes with the kinase CDK4/6, resulting in phosphorylation of RB which in turn drives G1/S progression (Fig 3).  Although most early stage prostate cancers retain wild-type RB function, perturbations in this pathway (loss of RB, upregulation of cyclin D) are felt to 
promote castration-resistance.    Preclinical data demonstrated that PD 0332991 (Palbociclib) inhibited proliferation and promoted G1 arrest in an RB and Cyclin D-dependent manner in prostate cancer cell lines and xenografts.
9  Thus, 
this laboratory data support the rationale for treating prostate cancers with intact RB function with palbociclib.  Currently, the rates of RB loss or mutation (as measured by array CGH or exome capture) ranges between roughly 1-20% in localized prostate can cer (1% for 2 copy deletion versus 
10-20% for 1 copy deletion)
15 to 30-40% in heavily treated metastatic castration-resistant p rostate 
cancer16. The reported rates of loss of RB protein expression, by immun ohistochemistry, range 
from 0% in prostatectomy series17 to 40% in primary (TURP) tum or specimens in CRPC patients 
(unpublished data, Karen Knudsen, Thomas Jefferson University) to 70% in metastases in CRPC 
patients.7  Although, there is little data examining RB loss in the hormo ne sensitive metastatic 
population we aim to study here, by extrapolation of existing d ata, we hypothesize the rate to be 
between 10-20%. 
 
We hypothesize that the addition of palbociclib to initial ADT in patients with newly metastatic 
RB-positive prostate cancer may significantly increase the efficacy of ADT.   We postulate that 
similar to the Phase II trial of palbociclib in breast cancer, responses and survival could be 
predicated on retention of wild-type RB function.  To assess this, we are conducting this 
randomized phase II study of palbociclib in which patients with newly diagnosed mHSPC and RB-expressing tumors based on metastatic disease biopsy will be ra ndomized (1:2) to ADT or ADT 
plus palbociclib.  We propose to use confirmed PSA response (< 4 ng/mL) after 
28 weeks  o f  
therapy as the primary endpoint because it is an intermediate e ndpoint that correlates significantly 
with overall survival in hormone-sensitive patients.18,19 
 
  

17 
 2.6 Correlative Studies Background and Rationale   
 Targeted Analysis of Potential Predictive Biomarkers
.   
As part of the patient selection for this trial, patients will undergo a metastatic disease biopsy which 
will be tested by immunohistochemistry (IHC) for total RB statu s in a CLIA certi fied laboratory.7  
Because the RB pathway can be disrupted in human cancers via di stinct mechanisms with distinct 
effects, additional correlative studies will be done to assess for potential biomarkers along and 
downstream of the RB pathway.5 For example, the RB protein can be inactivated by 
posttranslational modifications that are the subject of oncogen ic (e.g., cyclin D1 or cyclin D1B 
overexpression/amplification) or tumor suppressive (e.g., p16in k4a silencing) alterations. As 
previous studies from our group have defined a signature of RB loss, key RB target genes (such as Cyclin A and MCM7) will be assessed as potential biomarkers of response.
7  Given that RB 
interactors may also modulate the therapeutic response, the key RB interactor, E2F1, will be investigated as a predictive biomarker.  Finally, as RB also pl ays a critical role in the response to 
many antiproliferative stresses that are engaged by therapeutic  agents, the status of Ki-67, a 
common marker of cell proliferation, will be determined.
5  Immunohistochemical approaches for 
quantifying these potential biomarkers are described in Section  9. In total, these correlative studies 
will test the hypothesis that dist inct alterations in the RB pathway could modulate the response to 
commonly used therapeutic regimens.  While the potential biomarkers to be assessed in the correlativ e studies (i.e., p16, cyclin D1B, 
E2F1, etc) may modulate, interact with, or be an effector of th e RB pathway, each of these 
biomarkers is not completely specific for the RB pathway, and t herefore will be assessed as in 
secondary (correlative studies) instead of being included in th e primary eligibility criteria.  For 
example, in the case of p16, while RB deficiency causes p16 ove rexpression, many other biological 
processes (aside from RB deficiency) also cause p16 overexpress ion.  In general, it appears that 
p16 overexpression is twice as common as RB deficiency. In trip le negative breast cancers, there 
is a 25% chance of RB deficiency, but a 50% chance of p16 overexpression.
20  In prostate cancers, 
the rate of RB deficiency is estimated to be <10% in the mHSPC population.  However, a study 
using thousands of localized prostate cancer specimens (primari ly including Gleason 6/7 disease) 
showed that there was a 20% cha nce of p16 overexpression in thi s population,21 suggesting that 
the frequency of p16 overexpression will be at least 20% or hig her in the newly metastatic 
population. Therefore, given the fact that p16 is regulated by processes other than RB, and p16 
overexpression is approximately twice as common as RB loss, the  status of p16 and other RB 
modulators/interactors/effector s will be assessed in the correl ative studies but will not be used to 
exclude patients up front.  
  
Analysis for Additional Predictive  Biomarkers using Genomic Met hods.   To further uncover 
predictive markers, we will also perform targeted sequencing an d expression profiling on biopsy 
tissues. Genes commonly mutated in prostate cancer, those defin ing basic molecular subtypes, and 
those potentially related to RB will be assessed for point muta tions, short insertions/deletions 
[indels] as well as copy number alterations. Transcriptome sequ encing and/or qPCR will also be 
performed to assess expression of AR signaling, proliferation, molecular subtyping and RB-related genes. Given the challenges of  routinely assessing metastatic s ites, we will also perform the same 
sequencing on diagnostic specimens to determine concordance bet ween transcriptome/genome 
alterations in primary and metastatic samples. We hypothesize t hat there may be many additional 
molecular events which determine whether prostate cancers will respond to palbociclib. In 
18 
 addition, we will also perform exome capture and comprehensive next-generation sequencing on 
biopsy tissues if qualitatively and quantitatively sufficient R NA and DNA are recoverable.  Our 
team has previously initiated one of the first biomarker-strati fied randomized trials for patients 
with metastatic castration-resi stant disease (NCI 9012), entitled "A Randomized Gene Fusion 
Stratified Phase 2 Trial Of Abiraterone With Or Without ABT888 For Patients With Metastatic 
Castration-Resistant Prostate Cancer."  In the context of this trial, >70 biopsies (stored frozen) of 
metastatic disease were performed over the past 1.5 years, with  an 80% success rate of determining 
the status of the biomarker of interest.     
 While comprehensive sequenci ng studies have been performed in the context of locally advanced 
prostate cancer
22 as well as metastatic end-stage castration-resistant prostate cancer (CRPC),16 
there have been, to our knowledge, no such studies in the conte xt of metastatic hormone-sensitive 
prostate cancer.  Thus, by charac terizing the genome and transc riptome in this unstudied space, 
t h i s  p r o j e c t  w i l l  p r o v i d e  a  s i g n i ficant contribution to our kno wledge regarding the genomic 
landscape of prostate cancer, by providing an extensive look at  metastatic, but hormone-sensitive, 
prostate cancer.  This data would represent an extremely valuab le resource, which could serve as 
a "baseline" for comparison to s ubsequent sequencing studies in  the CRPC space, as well as an 
opportunity to identify targetabl e biological concepts that may  drive prostate cancer progression. 
 Analysis of blood specimens for c irculating, cell-free tumor DN A  
Recently, it has been demonstrated that patients with a variety of advanced solid tumors shed cell-free DNA (cfDNA) into the c irculation and that mutations p resent in tumor tissue can be 
detected by high-throughput seque ncing of cfDNA isolated from blood specimens.
23 This rapidly 
developing research area has the  potential of enabling the so-c alled "liquid biopsy", in which 
relevant genomic changes whic h currently need to be sought by b iopsy of metastatic sites could 
instead be assayed from a blood specimen. In the current study we will collect the matched blood 
specimens needed to evaluate the efficacy of this approach as a  surrogate for molecular analysis 
of tissue biopsy specimens. Once key predictive genomic biomark ers are identified from the 
tissue biopsy analyses above, t hey can be assayed in blood as w ell to determine concordance 
between blood and metastatic tissu e biopsy. Given that optimal methods for cfDNA analysis are 
rapidly evolving, we plan to use th e most current, robust techn ologies available when the time 
comes for analysis of the collected cfDNA specimens. 
 
Analysis for Additional Predictive Biomarkers in Circulating Tu mor Cells 
Assessment of circulating tumor cells potentially represents a “liquid biopsy” approach with the 
potential for identifying biomar kers of treatment response.  To enumerate and characterize 
circulating tumor cells in this study, we will utilize a platfo rm developed by Epic Sciences for 
CTC isolation and identificati on, which has previously been described.24-28  This platform allows 
for quantification of CTC number , as well as analysis of potent ial predictive biomarkers.  One 
potential biomarker of response is the heterogeneity of CTCs, as measured by distribution of 
previously characterized CTC subtypes, such as nucleoli CTCs, C TC clusters, CK- CTCs, CK 
speckled CTCs, small CTCs, AR nuclear CTCs, and AR cytoplasmic CTCs.29  The extent of 
CTC heterogeneity has been previo usly demonstrated to predict f or resistance to androgen 
targeting therapeutics.30 Thus, we hypothesize that CTC c ount and heterogeneity may pred ict for 
longer-term PSA responses, and wi ll explore this hypothesis in this study. 
 3. DRUG INFORMATION  
19 
  
3.1  IND Agent:  Palbociclib (Ibrance®) (PD 0332991) (unless otherwise specified, 
information is derived from Investigator’s Brochure). 
 
Chemical Name:  6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridi n-2-
yl)amino)pyrido[2,3-d]p yrimidin-7(8H)-one 
 
Other Names: Palbociclib, PD-0332991  
 Classification:  CDK4/6 Kinase Inhibitor  
 Molecular Formula: C
24H29N7O2  M . W . :   447.53  
 Mode of Action:  Palbociclib is a highly selective inhibitor of CDK 4/6 which bl ocks 
phosphorylation of the retinoblastoma protein. 
 
How Supplied:   Pfizer will supply Ibrance® for this study.  Ibrance® is suppli ed as capsules 
containing 75mg, 100mg or 125mg equivalents of palbociclib.  Th e capsules will be packaged 
in bottles contain ing 75mg, 100mg or 125mg capsules. 
Note:   Capsules should not be repackaged after they are dispensed.  Capsules should not 
be opened or emptied into another  vehicle for oral ingestion.  Capsules should be 
swallowed intact. 
Storage:   Store at controlled room tempe rature (15-30C, 59-86F) in thei r original container.
  
 
Route(s) of Administration:  Oral 
 Method of Administration:  Capsules should be swallowed whole without chewing.  
Patients should take doses at appr oximately the same times each  d a y  a n d  r e c o r d  t h i s  
information in the patient diary .  Patients should take palboci clib with food.  Patients will take 
medication daily for 21 days of a 28 day cycle. 
 Metabolism:  The ability of cytochrome P450 enzymes to metabolize palbocicl ib   was 
evaluated by incubation of palbociclib (6 M) with the 5 major cytochrome P450 (CYP) 
enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). CYP3A4 was the only 
enzyme that metabolized palbociclib. Concordantly, metabolism o f palbociclib (6 M) in 
human liver microsomes was significantly reduced (>80% decrease ) in the presence of the 
CYP3A4 enzyme-specific inhibitor ketoconazole (1 M). These data indicate that CYP3A 
enzymes are the primary enzymes responsible for the metabolism of palbociclib. 
   
Potential Drug Interactions:  Palbociclib is primarily metabolized by CYP3A4.  
Coadministration with strong CY P3A4 inhibitors or inducers may significantly change 
plasma concentrations in humans.  Therefore the concurrent  use of strong inhibitors such 
as amprenavir, atazanavir, boceprevir, clarithromycin, conivapt an, delavirdine, 
diltiazem, erythromycin, fosamp renavir, indinavir, itraconazole , ketoconazole, 
lopinavir, mibefradil, miconazol e, nefazodone, nelfinavir, posa conazole, ritonavir, 
20 
 saquinavir, telaprevir, telithromycin, verapamil, voriconazole,  and grapefruit  or strong 
inducers such as carbamazepine, felbamate, n evirapine, phenobar bital, phenytoin, 
primidone, rifabutin, rifampin, rifapentin and St. John’s wort are not allowed. 
 
Excretion:   The excretion balance of radio activity and radioactivity conc entration in the 
collected plasma and blood sample s were evaluated following ora l administration of [14C] 
palbociclib (ethanesulfonic salt ) to intact and bile-duct cannu lated (BDC) male and female 
Sprague-Dawley rats at the dose level of 50 mg/kg as salt. The radioactive dose was mainly 
eliminated via the feces (>82%) with minor contribution of urin ary excretion (7.8%). The 
percentage of dose eliminated in bile within 72 hours after dos ing was 53% in male and 
82% in female BDC rats, suggesting that biliary excretion is th e major route of elimination 
in rats.   Toxicology:   The primary palbociclib toxicities in preclinical studies are  to the bone 
marrow, lymphoid tissues, and test es. These toxicities occurred in both rats and dogs, and 
are consistent with cell cycle inhibition produced by the inten ded pharmacology of the 
drug. Bone marrow pancytopenia re sulted in decreases in various  hematology parameters; 
however, the changes were reversible following cessation of dos ing. Reversible 
myelosuppression is anticipated in clinical studies and may be dose-limiting. Palbociclib 
demonstrated a potential for aneugenicity in the in vitro and i n vivo micronucleus assays. 
Acute IV administration of palbociclib to anesthetized dogs res ulted in significant 
pulmonary effects, including apnea, which were reversible. Effects were transient, appeared related to peak plasma concentrations (>2040 ng/mL), a nd consistent with 
centrally-mediated respiratory depression. No changes in pulmon ary function occurred at 
plasma drug concentrations <414 ng/mL. Pulmonary changes were o bserved in rats to 
which palbociclib was administer ed orally, which included rales , dyspnea, and atrophy of 
tracheal epithelium. The clinical relevance of these effects is  unknown. Results of the 
Purkinje fiber and hERG in vitr o assays and cardiovascular stud y in dogs have indicated a 
potential for prolongatio n of the QT interval  
 Additional routine studies in ra ts revealed that palbociclib co uld alter glucose metabolism 
and affect the pancreas, eye, teeth, kidney and adipose tissue of some rats. Hyperglycemia, 
glycosuria and pancreatic islet cell changes were observed.  So me rats developed cataracts 
(clouding of the eye lens) after being given palbociclib for 6 months.  It is currently 
unknown what these findings mean f or patients treated with palb ociclib over time. 
 
Pharmacokinetics in Humans:    
 
As of 10 December 2014, twenty-one c linical studies have evalua ted the PK of 
palbociclib.  Four of these tri als were conducted in patients w ith advanced malignant 
disease.  Seventeen Phase 1 cli nical pharmacology and biopharmaceutic studies of 
palbociclib were conducted in healthy subjects.  Ten of these 17 clinical trials were 
clinical pharmacology studies condu cted to investigate the abso rption, distribution, 
metabolism, and excretion of palbociclib as well as examine the  potential for a drug-drug 
interaction (DDI) with palbociclib.  The remaining 7 of the 17 clinical trials were 
biopharmaceutic studies conducted 
to examine the bioavailabilit y, bioequivalence, and 
food effect of the palbociclib formulations.   
21 
  
Pharmacokinetic (PK) data from patients with advanced cancer from Study A5481001 indicate that the plasma pharm acokinetics of palbociclib are lo w to moderately variable 
with generally dose proportional exposures over the dose range evaluated (25 mg to 225 
mg) following single and multiple doses.  PK data from Studies A5481001, A5481003, 
and A5481010 indicate that palbocic lib is slowly absorbed with a median time of 
maximum concentration (T
max) between 4 and 8 hours post-dose, and is slowly 
eliminated with an elimination half-life (t 1/2) ranging from 23.2 hours to 28.8 hours.  
Palbociclib accumulates after repeated daily dosing (median Rac ranged from 1.9 to 2.4), which was consistent with its terminal t
1/2. In Study A5481010, the median R ss (the 
predicted accumulation to estim ate linearity) was 1.1, indicati ng that palbociclib 
clearance does not change  over time.  In Study A5481003, palboc iclib was shown to 
achieve steady-state concentra tions following 8 days of QD dosi ng.  The palbociclib 
geometric mean volume of distribution (V z/F) was 2583 L in women with advanced 
breast cancer (Study A5481003), which is significantly greater than total body water (42 
L), indicating that palbociclib ext ensively distributes to peri pheral tissues. 
 In humans, metabolism is the major route of elimination of palb ociclib. Following a 
single oral administration of [
14C]palbociclib to healthy subjects (Study A5481011), the 
overall median recovery of the ad ministered radioactivity in th e excreta was 91.6% with a 
median of 17.5% recovered in urine and a median of 74.1% recove red in feces.  
Excretion of unchanged palbociclib in the feces and urine was 2 .3% and 6.9% of dose, 
respectively, indicating that exc retion plays a minor role in e limination of palbociclib.  A 
study in healthy volunteers (A5481015)  indicated that the absol ute oral bioavailability of 
palbociclib was approximately 46%.    
In vitro data indicate that CYP3A and SULT enzyme SULT2A1 are mainly involved in 
the metabolism of palbociclib.  Pal bociclib is a weak time-depe ndent inhibitor of CYP3A 
following daily 125 mg dosing to steady state in humans.  In vi tro, palbociclib is not an 
inhibitor of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, and 2D6, and is not an inducer of 
CYP1A2, 2B6, 2C8, and 3A4 at clini cally relevant concentrations . 
 
In vitro evaluations indicated t hat palbociclib has a low poten tial to inhibit the activities 
of drug transporters P-glycoprot ein (P-gp), breast cancer resis tance protein (BCRP), 
organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)2, organic anion transporting polypeptide (OATP)1B1, OATP1B3, and bile sal t export pump 
(BSEP) at clinically relevant concentrations.  An itraconazole DDI study in healthy volunteers (Study A5481016) and a rifampin DDI study in healthy volunteers (Study A 5481017) were conducted to evaluate the potential 
for strong CYP3A inhibitors and inducers, respectively, to alte r the PK of palbociclib. 
Coadministration of itraconazole  and palbociclib increased palbociclib AUC
inf and C max 
by approximately 87% and 34%, resp ectively, relative to those w hen palbociclib dose 
was given alone.  Coadministration of rifampin and palbociclib decreased palbociclib 
AUC inf and C max by approximately 85% and 70%, respe ctively, relative to palboc iclib 
given alone.  Based on this data, t he concurrent administration  of strong CYP3A 
inhibitors and inducers wit h palbociclib should be avoided. 
22 
  
A midazolam DDI study in heal thy volunteers (Study A5481012) wa s conducted to 
evaluate the potential for pal bociclib to act as a time-depende nt inhibitor of  CYP3A4/5 at 
steady-state.  Plasma midazolam C max and AUC inf values increased 37% and 61%, 
respectively, when single oral doses of midazolam were co-admin istered with multiple 
doses of palbociclib as compared to its administration alone. T his is consistent with weak 
time-dependent CYP3A4/5 inhibiti on mediated by palbociclib at s teady-state following 
daily 125 mg dosing.  PK data from the Phase 1 portion of Study A5481003 was analyzed to evaluate the potential for a DDI between palboc iclib and letrozole at steady -state.  These data indicate 
a lack of a potential for DDIs  between palbociclib and letrozol e when administered in 
combination.   Data from a DDI study in healthy m ale subjects indicated that palbociclib exposures were 
comparable when a single dose of  palbociclib was coadministered with multiple doses of 
tamoxifen and when palbociclib was given alone.  The effect of food on the exposure of palbociclib when administ ered as the commercial 
free base capsule was evaluat ed in healthy subjects (A5481021).   Compared to 
palbociclib given under overnight fasted conditions, the AUC
inf and C max of palbociclib 
increased by 21% and 38% when given with high-fat food, by 12% and 27% when given 
with low-fat food, and by 13% and 24%  when moderate-fat food wa s given 1 hour before 
and 2 hours after palbociclib dos ing.  In addition, food intake  significantly reduced the 
intersubject and intrasubject v ariability of palbociclib exposu re.  Based on these results, 
palbociclib commercial free base capsules should be taken with food. 
 The solubility of the palbociclib free base is pH dependent—pal bociclib is water soluble 
at low pH (2.1-4.5), while the s olubility dramatically decrease s as pH rises above 4.5.  
Concomitant administration of age nts which increase gastric pH can alter the solubility 
and absorption of palbocicli b free base formulations.  
 In a drug interaction trial i n healthy subjects (A5481038), coa dministration of a single 
125 mg dose of commercial free base capsule with multiple doses  of the proton pump 
inhibitors (PPI) rabeprazole  under fed conditions decreased pal bociclib C
max by 41%, but 
had limited impact on AUC inf (13% decrease), when compared to a single dose of 
palbociclib administered alone .  Given the reduced effect on ga stric pH of H2-receptor 
antagonists and local antacids compared to PPIs, the effect of these classes of acid-
reducing agents on palbociclib e xposure under fed conditions is expected to be minimal.  
Under fed conditions there is no c linically relevant effect of PPIs, H2-receptor 
antagonists, or local antaci ds on palbociclib exposure.  In ano ther healthy subject study, 
coadministration of a single dose  of commercial free base capsu le with multiple doses of 
the PPI rabeprazole under fasted conditions decreased palbocicl ib AUC inf and C max by 
62% and 80%, respectively, when c ompared to a single dose of pa lbociclib administered 
alone.  Collectively, these antac id DDI data further support th e requirement that the free 
base capsule of palbociclib should be taken with food.  
23 
 Based on a population pharmacokine tic analysis in 183 patients with cancer (50 male and 
133 female patients, age ra nge from 22 to 89 years, and body weight range from 37.9 to 
123 kg), gender had no effect on the exposure of palbociclib, and age and body weight 
had no clinically important effect  on the exposure of palbocicl ib. 
 Based on a population pharmacokinetic  analysis that included 18 3 patients, where 40 
patients had mild hepatic impairm ent (total bilirubin ≤ ULN and  AST > ULN, or total 
bilirubin >1.0 to 1.5 × ULN and any A ST), mild hepatic impairme nt had no effect on the 
exposure of palbociclib.  The pharm acokinetics of palbociclib h ave not been studied in 
patients with moderate or severe hepatic impairment (total bili rubin >1.5 × ULN and any 
AST).  Based on a population pharmacokinetic  analysis that included 18 3 patients, where 73 
patients had mild renal impairmen t (60 mL/min ≤ CrCl <90 mL/min ) and 29 patients had 
moderate renal impairment (30 mL/min ≤ CrCl <60 mL/min), mild a nd moderate renal 
impairment had no effect on the exp osure of palbociclib.  The p harmacokinetics of 
palbociclib have not been studied  in patients with severe renal  impairment. 
 A pharmacokinetic/pharmacodynamic analysis to evaluate the relationship between 
palbociclib exposure and ECG endpoi nts (RR and QTc intervals) w ere developed using 
pooled data from 3 clinical trials in patients with advanced ma lignant disease (Studies 
A5481001, A5481002, and A5481003).  The s tudy population consis ted of 48 men and 
136 women with a median (rang e) body weight of 73.0 (37.9-123) kg and age of 
61.5 (22-89) years old.  Palbociclib  doses ranged from 25 mg to 225 mg QD.  The data 
collected from 184 patients cons isted of 569 ECG-palbociclib co ncentration-matched 
pairs; the observed plasma concentrations had a median (range) of 55.2 (2.51-329) 
ng/mL.  The average heart rate, RR, QT, QT corrected for heart rate according to Bazett 
(QTcB), QT corrected for heart ra te according to Fridericia (QTcF), and QTcS (QT 
interval corrected for heart rate according to a study-specific  correction factor) at baseline 
for ECG-palbociclib concentra tion matched data were 76.8 beats per minute, 808 msec, 
380 msec, 425 msec, 409 msec, and 412 msec, respectively. 
 The results of the analysis i ndicate that palbociclib does not appear to have a 
concentration-dependent eff ect on heart rate.  A slight positiv e linear relationship 
between palbociclib concentration and QTcS was observed; howeve r, at the mean or 
median steady-state palbociclib C
max following administra tion of the recommended 
clinical dose of palbociclib (125 mg QD) in patients with cance r, the upper bound of the 
one-sided 95% CI for the increase in QTcS fell below the thresh old of 10 msec, 
suggesting that QT prolongation is  not a safety concern for palbociclib at the 
recommended clinical dose according to the criteria described i n the ICH guidance for 
Industry E14.  Similar results wer e obtained when QTcF and QTcB  were used. 
  Metabolism in Humans:    A s s e s s m e n t  o f  t h e  p l a s m a  s a m p l e s  o n  D a y  1 4  o f  C y c l e  1  
indicated that the glucuronide c onjugate of palbociclib and the  lactam of palbociclib (PF-
05089326) were the main metabolites  present in pla sma. Other me tabolites observed were 
the glucuronide conjugates of hydroxylated palbociclib and the glucuronide conjugate of 
24 
 reduced palbociclib. PF-05089326 was also observed in the circu lation of rats following 
repeated daily oral administration of palbociclib at the dose l evels of 50 and 100 
mg/kg/day. 
 
Safety and Adverse Events: 
 
Phase 1 Trials:13,31 
The most frequently reported treatment-emergent adverse events (TEAEs) (>20% of 
patients) of any grade, regardless of causality were fatigue (52.7% of patients); neutropenia (48.4%); nausea (35.2%); diarrhea and anemia (30.8% each); cons tipation (26.4%); 
decreased appetite (22.0%); and vomiting and thrombocytopenia (20.9% each). The most frequently reported TEAEs (>20% of patients) of any grade that were considered to be 
related to the study treatment were neutropenia (46.2% of patie nts); fatigue (45.1%); 
diarrhea and anemia (25.3% each); and nausea (24.2%). 
 
The most frequently reported Grade > or = 3 TEAEs, all causalit y, were neutropenia 
(30.8% of patients); anemia (9.9%); leukopenia (7.7%); fatigue (6.6%); and dyspnea and 
disease progression (5.5% each). Grade 3 neutropenia was consid ered to be related to the 
study treatment for 22.0% of patients. Grade 3 leukopenia and t hrombocytopenia were each 
considered related to treatment in 5.5% of patients. 
 
The most frequently reported Grad e 4 TEAEs were neutropenia (6 patients; all considered 
to be related to the study treatment) and thrombocytopenia (3 p atients; considered to be 
related to study treatment for 2 patients). Grade 4 leukopenia was reported for 2 patients 
and Grade 4 anemia, pulmonary embolism, increased blood uric ac id, decreased 
hemoglobin level and hyperglycemia for 1 patient each. Grade 5 events were reported for 
8 patients and included disease progression (5 patients), cardi ac arrest (2 patients) and 
failure to thrive (1 patient). N o Grade 5 event was considered to be related to palbociclib. 
 Phase 1/2  Trial:
14 
In the Phase 1/2 trial, the most frequently reported TEAEs (>20 % of patients) of any grade, 
regardless of causality were neut ropenia (71.6% of the patients); leukopenia (41.1%); 
fatigue (40.0%); nausea (27.4%); anemia (26.3%); diarrhea (22.1 %); and arthralgia and hot 
flush (20.0% each). All reports of neutropenia and leukopenia w ere considered to be related 
to the study treatment. Fatigue and anemia were considered to be related to the study treatment for 25.3% of patients each, nausea for 18.9%, hot flu sh for 17.9%, and arthralgia 
for 16.8%. The most frequently reported Grade 3 TEAEs were neutropenia (53.7% of patients) and leukopenia (17.9% o f patients). All reports of neutropenia and leukopenia 
were considered to be related to the study treatment. The most frequently reported Grade 
4 TEAEs were neutropenia (6.3% of patients; all considered to b e related to study 
treatment), fatigue and pulmonary embolism (2.1% of patients ea ch; all considered to be 
unrelated to treatment). As of the 01 September 2012 cutoff, on e Grade 5 event (disease 
progression considered unrelate d to study treatment) was report ed. 
 Duration of Toxicity: 
An exploratory analysis assessi ng the duration of neutropenia a nd thrombocytopenia 
during the first 2 cycles of treatment with palbociclib showed that neutropenia and 
25 
 thrombocytopenia were dose dependent, with both nadirs observed  at the end of the dose 
period. In most patients, both cell counts recover during the off-treatment period at the end 
of the cycle. No significant differences appeared when nadir va lues during Cycle 1 and 
Cycle 2 were compared, suggesting that myelotoxicity was not cu mulative. 11 first cycle 
dose-limiting toxicities (DLTs) were noted, 5 for patients on S chedule 3/1 and 6 for patients 
on Schedule 2/1. All DLTs consisted of neutropenia and/or throm bocytopenia and most 
were categorized as a DLT due to the need for a treatment inter ruption of longer than 7 
days’ duration. Febrile neutropenia was not reported as a DLT.  
 Effect on QT interval: 
The results of analysis of 3 clinical trials demonstrates that palbociclib does not appear to 
have a concentration dependent e ffect on the hea rt rate.  There  was a possible relationship 
between palbociclib and QTc although the increase fell below th e threshold of 10 msec 
suggesting that QT prolongation is not a major safety concern at the recommended doses. 
 
Adverse Events with Possibl e Relationship to Palbociclib 
Likely (>20%) Less Likely (<20%) Rare but Serious (<3%) 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
Neutropenia Lymphopenia 
 Febrile Neutropenia 
Anemia  Bone Marrow Failure 
Thrombocytopenia  Anemia 
Leukopenia   
CARDIAC DISORDERS 
 Palpitations Unstable Angina 
Pericarditis 
EYE DISORDERS 
 Vision Blurred Retinal Hemorrhage 
 Conjunctivitis Bilateral Cataracts 
 Increased Tear Production  
GASTROINTESTINAL DISORDERS 
Nausea Constipation Ischemic Colitis 
Diarrhea Vomiting Diarrhea 
 Abdominal Pain  
 Flatulence  
 Abdominal Distension  
 Abdominal Discomfort  
 Dry Mouth  
 Dyspepsia  
 Stomatitis  
 Gum Pain  
 Mouth/Throat Pain  
GENERAL DISORDERS AND ADMI NISTRATION SITE CONDITIONS 
Fatigue Peripheral Edema Pyrexia 
 Pain Sudden Death 
 Pyrexia Otitis Media Acute 
26 
  Chills  
 Mucosal Inflammation  
 Chest Pain  
 Asthenia  
 Pain During Urination  
INFECTIONS  
 Upper Respiratory Tract 
Infection Bronchopneumonia 
 Nasopharyngitis Pneumonia 
 Pneumonia Urinary Tract Infection 
 Bronchitis Disseminated Herpes Zoster
 Viral Infection Sepsis 
 Urinary Tract Infection Pyelonephritis 
METABOLISM and NUTRITIONAL DISORDERS 
 Decreased Appetite Dehydration 
 Hypokalemia Metabolic Acidosis 
 Hyperglycemia Elevated Liver Enzymes 
  Hepatic Failure 
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
 Arthralgia  
 Back Pain  
 Muscle Spasms  
 Flank Pain  
 Muscular Weakness  
 M yalgia  
 Pain in Extremity  
 Musculoskeletal Chest Pain  
 Tooth ache  
 Bone Pain  
NERVOUS SYSTEM DISORDERS 
 Neuropathy peripheral  
 Headache  
 Dizziness  
 Dysgeusia  
 Hypoesthesia  
 Falling Down  
PSYCHIATRIC DISORDERS 
 Anxiety Suicide Attempt 
 Depression  
 Insomnia  
 Altered Mood  
RESPIRATORY, THORACIC and MEDIASTINAL DISORDERS 
 Dyspnea Allergic Alveolitis 
 Cough Respiratory Failure 
 E pistaxis  
27 
  Rhinorrhea  
 Oropharyngeal Pain  
 Exertional Dyspnea  
SKIN and SUBCUTANEOUS  TISSUE DISORDERS 
 Rash  
 Alopecia  
 Pruritus  
 Night Sweats  
 Nail Disorder  
 Dry Skin  
VASCULAR DISORDERS 
Hot flush Hypertension Deep Vein Thrombosis 
 Hypotension  
INVESTIGATIONS 
 Blood Creatinine Increased  
 Hemoglobin Decreased  
 Neutrophil Count Decreased  
 White Blood Cell Count 
Decreased  
 Blood Potassium Decreased  
 Weight Decreased  
 Weight Increased  
  
N O T E :  P a l b o c i c l i b  i n  c o m b i n a t i o n  w i t h  A D T  c o u l d  c a u s e  a n  e x a c e r bation of any 
adverse event currently known to be caused by the other agent, or the combination 
may result in events never previously associated with either agent.    
Special Handling:  Handle palbociclib according to institutional guideline for haz ardous 
drugs.  
 Availability: Palbociclib is an experime ntal agent supplied by Pfizer . 
 
Drug Accountability:   The investigator, or a respons ible party designated by the 
investigator, must maintain a c areful record of the inventory a nd disposition of the 
investigational drug, palbobcic lib.   The drug accountability r ecords will capture drug 
receipt, drug dispensing, drug return and final disposition. 
 
***Commercial Agents: For this study, bicalutamide, goserelin acetate and leuprolide acetate or 
equivalent LHRH agonists are co mmercially available; therefore,  Investigator Brochures are not 
applicable to these drugs. Information about commercial drugs i s publicly available in the 
Physician’s Desk Reference (PDR ), prescribing information and o ther resources. 
 
 
3.2  Bicalutamide (Casodex®) (NSC-722665) 
 
28 
 General:    Bicalutamide is an active non-steriodal antiandrogen a nd its antiandr ogen activity 
resides exclusively in the (-) or (R) enantiomer. Unlike flutam ide, it is peripherally selective 
and does not cause a rise in serum LH or Testosterone in male rats and dogs. This peripheral 
selectivity may be because it penetrates poorly the CNS and Hyp othalamus (the site of negative 
feedback of androgens). In humans, rises in LH, Testosterone an d Estradiol concentrations 
were seen. These rises were not dose related. In 90%, testoster one levels remained within 
normal limits. There was no significant rise in mean serum FSH.   
 Chemistry:  Bicalutamide is a racemic mixture containing two enantiomers, (2RS)-4'-Cyano-
3(4-fluorophenylsulphonyl)-2-hydrox y-2-methyl-3'-trifluoromethyl) propionanilide. 
 Toxicology:  In rats, besides antiandrogenic changes, there was evidence of  hepatocyte 
hypertrophy and basophilia. In dogs treated for 6 months, there  was increased heart rate with 
decreased PR interval, transient decrease in circulating PMNs a nd increased plasma 
cholesterol. No cardiac pathology was found. In a mouse oncogen icity study, an increased 
incidence of hepatocellular carcinoma was observed in the top d ose male group (75 
mg/kg/day). The no effect dose level for hepatocellular carcino m a  i n  t h i s  s t u d y  w a s  1 5  
mg/kg/day with steady state blood levels in excess of 10 μg/ml.  The mechanism for this tumor 
formation is a non-genotoxic, phenobarbitone-type MFO induction  and is not considered to 
represent a risk for humans. A t wo-year study in rats and femal e mice at similar 
doses did not show an increased incidence of hepatic tumors. Bi calutamide has been given to 
over 3,500 men in 35 different clinical studies worldwide, in d oses up to 600 mg daily. When 
bicalutamide is given in combina tion with an LHRH analog, the p harmacologic adverse event 
profile is dominated by the LHRH analog an d includes hot flashe s (53%), gynecomastia (9%) 
and breast pain (6%). Other advers e events reported regardless of 
causality included diarrhea (12%), constipation (22%), nausea (15%) and abdominal pain 
(11%). Other adverse were reported, such as fatigue (22%), pain (35%), back pain (25%), 
pelvic pain (21%), infection (18 %), peripheral edema (13%), dys pnea (13%), nocturia (12%), 
hematuria (12%), anemia (11%), dizziness (10%). Bicalutamide ha s been associated with 
changes in liver function, although these are infrequent (7%) a nd rarely occur with jaundice. 
Many of these changes improved or  resolved despite continuation  of bicalutamide therapy. 
There have been no reports of fat al hepatotoxicity associated w ith bicalutamide therapy. 
 PHARMACOLOGY: 
 Pharmacokinetics: Animal studies : After oral single dose administration, absorption of the 
compound was slow with peak con centration occurring 3 - 12 hour s and plateau between 
2 and 48 hours. There was non-proportional increase in plasma l evels with increasing 
doses. Elimination half-life ranges from 17 - 28 hours in male rats, 21 - 29 hours in female rats and 5 - 7.5 days in dogs. 91 - 96% of bicalutamide is boun d to plasma protein. Human 
studies: After single doses, mean time for peak plasma concentr ation was 6 hours at 10 and 
30 mg, but at 50 mg, it was 16 hours. Mean plasma elimination h alf-lives after 12 weeks 
of 10, 30, 50, 100 mg/day was 7 - 10 days. This finding was con sistent with single dose 
data. In patients given daily doses of 50 mg, mean plasma conce ntration was 10 µg/mL at 
12 weeks. After single doses, there was linear increase with do ses between 10 and 50 mg, 
but became non-linear at doses of 50 - 100 mg. At 100 mg, the o ral bioavailability is 
reduced by 30% but plasma elimination half-life is unchanged. B icalutamide is extensively 
metabolized and metabolites are excreted by both the biliary an d urinary system. 
29 
  
 Formulation: Bicalutamide is prepared as round, film-coated green or white tablets 
containing standard recipients a nd 50 mg of the drug. Storage a nd stability: All packages 
of bicalutamide should be stored  securely in a dry place at roo m temperature. 
 
 Route of Administration: Bicalutamide is to be administered in tablet form as a once-daily 
oral dose. Patients should be i nstructed to take one tablet onc e daily. 
 
 Supplier: Commercial supply of Bicalutamide will be used. Pleas e refer to the Physician 
Desk Reference and package insert for complete information. 
 
3.3 Goserelin acetate implant (Zoladex®) (NSC-606864) 
 
 PHARMACOLOGY  
 Mechanism of Action: Following initial administration in males,  goserelin causes an initial 
increase in serum luteinizing hormone (LH) and follicle stimula ting hormone (FSH) levels 
with subsequent increases in serum levels of testosterone. Chro nic administration of 
goserelin leads to sustained suppression of pituitary gonadotro pins, and serum levels of 
testosterone consequently fall i n t o  t h e  r a n g e  n o r m a l l y  s e e n  i n  surgically castrated men 
approximately 2-4 weeks afte r initiation of therapy. 
 Absorption: Goserelin 3.6 mg is released slowly in first 8 days , and then rapid and 
continuous release for the remainder of the 28 day dosing perio d. Time to peak 
concentration for goserelin 3.6 mg is 12-15 days in males and 8 -22 days in females. 
Goserelin 10.8 mg exhibits an init ial rapid release resulting i n a peak concentration at 2 
hours after dosing. From Day 4 until the end of the 12-week dos ing interval, the sustained 
release of goserelin produces a r easonably stable systemic expo sure.  
 Distribution: Apparent volumes of distribution determined after  subcutaneous 
administration of 250 mcg aqueous solution of goserelin were 44.1 and 20.3 liters for males and females, respectively. Goser elin is approximately 27% prote in bound. 
 Metabolism: Metabolism of goserelin by hydrolysis of the C-term inal amino acids is the 
major clearance mechanism. The half-life elimination (t1/2)) is  approximately 4 hours in 
males and 2 hours in females.  
 Elimination: Clearance of goserelin is very rapid and occurs pr imarily via urinary excretion 
(>90%; 20% as unchanged drug).  
 Drug Interactions: Luteinizing hormone-releasing hormone analog s may diminish the 
therapeutic effect of antidiabetic agents. No formal drug-drug interaction studies have been 
performed. Please refer to the current FDA-approved package ins ert for additional 
information. 
    ADVERSE EVENTS- Please refer to package insert or company webs i t e  f o r  u p  t o  d a t e  
information. 
Adverse Events with Possibl e Relationship to Goserelin 
Likely (>20%) Less Likely (<20%) Rare but Serious (<3%) 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
30 
  Anemia  
CARDIAC DISORDERS 
 Congestive Heart Failure Cerebrovascular Accident 
 Hypertension Myocardial Infarction 
 Palpitation  
 Vasodilatation  
 Tachycardia  
EYE DISORDERS 
 Amblyopia  
 Dry Eyes  
GASTROINTESTINAL DISORDERS 
 Anorexia  
 Appetite increase  
 Nausea  
 Abdominal Pain  
 Constipation  
 Diarrhea  
 Dyspepsia  
 Flatulence  
 Ulcer  
 Vomiting  
 Xerostomia  
GENERAL DISORDERS AND ADMI NISTRATION SITE CONDITIONS 
Sweating Injection site reaction  
Tumor Flare Voice Alterations  
IMMUNE SYSTEM DISORDERS 
 Fever  
INFECTIONS  
 Infection  
 Flu Syndrome  
METABOLISM and NUTRITIONAL DISORDERS 
 Weight gain/loss  
 Hyperglycemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
Bone mineral density 
decrease Weakness  
 Arthralgia  
 Back pain  
 Hypertonia  
 Bone/Joint Pain  
 Leg Cramps  
 M yalgia  
 Paresthesia  
NERVOUS SYSTEM DISORDERS 
Headache Dizziness  
31 
  Pain  
PSYCHIATRIC DISORDERS 
 Anxiety  
 Depression  
 Insomnia  
 Emotional lability  
RENAL and URINARY DISORDERS 
 Urinary Frequency  
 Urinary Obstruction  
 Urinary Tract Infection  
REPRODUCTIVE SYSTEM and BREAST DISORDERS 
Hot flashes/sweats Pelvic Symptoms  
Libido Decreased Breast Enlargement  
Sexual Dysfunction Erections Decreased  
Breast Atrophy Libido Increased  
 Breast Pain/Swelling  
RESPIRATORY, THORACIC and MEDIASTINAL DISORDERS 
 Pharyngitis  
 Upper Respiratory Infection  
 C OPD  
 Cough  
 Bronchitis  
 Sinusitis  
 E pistaxis  
 Rhinitis  
SKIN and SUBCUTANEOUS  TISSUE DISORDERS 
Acne Hair Disorders  
Seborrhea Hirsutism  
 Pruritus  
 Rash  
 Skin Discoloration/Bruising  
VASCULAR DISORDERS 
Peripheral Edema Hemorrhage Thromboembolism 
 
 Adverse effects occurring in <1%, post marketing, and/or case reports: ALT increased, 
anaphylaxis, AST increased, diabetes, glucose tolerance decreas ed, hypercalcemia, 
hypercholesterolemia, hyperlipidemia, hypersensitivity reaction s, hypotension, ovarian cyst, 
pituitary apoplexy, psychotic  disorders, urticarial. 
  The FDA issued a safety communication in October 2010 based on  their ongoing safety review 
of LHRH agonists. The safety co mmunication discusses the potential for an increased risk of 
diabetes and cardiovascular disease (myocardial infarction, sud den cardiac death, stroke) 
associated with these agents. The risk is thought to be low in men receiving LHRH agonists for 
prostate cancer. In this trial, LHRH agonists are being adminis tered for a short period of time. 
FDA recommendations include management of cardiovascular risk f actors according to current 
standards of practice. 
32 
  
 DOSING & ADMINISTRATION 
1. Dosing – See Treatment Plan 
2. Goserelin is administered subcutaneously 
 
 STORAGE & STABILITY: Refer to t he current FDA-approved package insert for storage, 
stability and special  handling information. 
  HOW SUPPLIED 
1. Goserelin acetate implant is available in a 3.6 mg or 10.8 mg d isposable syringe device. 
The unit is sterile and comes in a sealed, light- and moisture- proof, aluminum foil laminate 
pouch containing a desiccant capsule. 
2. Commercial supply of Goserelin will be used. Refer to the curre nt FDA-approved package 
insert for additional information.  
 3.4 Leuprolide (Lupron Depot®) (NSC-377526) 
 
 PHARMACOLOGY  
 Mechanism of Action: Leuprolide inhibits gonadotropin secretion  by acting as an 
luteinizing hormone-releasing hor mone (LHRH) agonist. Continuou s administration 
results in suppression of ovari an and testicular steroidogenesi s due  to  decreased  levels  
of  LH  and  FSH  with  subsequent  decrease  in testosterone (male) and estrogen (female) levels. In males, testosterone levels are reduced to below cast rate levels. Leuprolide may 
also act directly on the testes as well as act by a different m echanism not directly related to 
reduction in serum testosterone. 
 Absorption: After the initial increase of leuprolide following each injection, mean serum 
concentrations remain relatively constant.  
 Distribution: The mean steady-state volume of distribution of l euprolide following 
intravenous bolus administration to healthy male volunteers was  27 L. In vitro binding to 
human plasma proteins ranged from 43% to 49%. 
 Metabolism: Upon   administrati on   with   differe nt   le uproli de   acetate formulations, the 
major metabolite of leuprolide acetate is a pentapeptide (M-I) metabolite.  
 Elimination: Less  than  5%  of  the  leuprolide  dose  was  re covered  as parent  and  M-I  
metabolite  in  the  urine  following  the  3.5  mg  depot inje ction.  
 Drug Interactions: Lute inizing hormone-releasing hormone analog s may diminish the    
therapeutic    effect    of    a ntidiabetic    agents.    No ph armacokinetic-based drug-drug   
interaction   studies   have   been performed. Because leuproli de is a peptide that is primarily 
degraded by peptidase and not by Cytochrome P-450 enzymes and t he drug is only about 
46% protein bound, drug interacti ons would not be expected to occur. 
 
  ADVERSE EVENTS- Please refer to package insert or company websi t e  f o r  u p  t o  d a t e  
information.   
Adverse Events with Possibl e Relationship to Leuprolide 
33 
 Likely (>20%) Less Likely (<20%) Rare but Serious (<3%) 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
 E dema  
CARDIAC DISORDERS 
 Hyper/Hypotension Arrhythmia 
 Tachycardia Atrial Fibrillation 
 Bradycardia Congestive Heart Failure 
 Angina Syncope 
 Palpitation  
GASTROINTESTINAL DISORDERS 
Nausea Altered Bowel Function Gastrointestinal Hemorrhage 
Vomiting Ulcer  
 Intestinal Obstruction  
 Constipation  
 Diarrhea  
 Gastroenteritis/Colitis  
GENERAL DISORDERS AND ADMI NISTRATION SITE CONDITIONS 
Local Injection site 
burning/stinging Skin reaction  
IMMUNE SYSTEM DISORDERS 
 Flu-like syndrome Allergic Reaction 
INFECTIONS  
 Urinary Tract Infection  
 Infection  
INVESTIGATIONS 
 BUN increase  
 Creatinine increase  
 Bicarbonate decrease  
 Hyperphosphatemia  
 Hyperuricemia  
 Hypoalbuminemia  
 Hypoproteinemia  
METABOLISM and NUTRITIONAL DISORDERS 
 Dehydration  
 Hyperlipidemia  
 Weight gain/loss  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS 
 Weakness  
 Bone Pain  
 Joint Disorder  
 M yalgia  
 Paresthesia  
NERVOUS SYSTEM DISORDERS 
Headache Nervousness Seizure 
Pain Anxiety  
34 
 Insomnia Confusion  
 Fatigue  
 Dizziness/vertigo  
PSYCHIATRIC DISORDERS 
Depression   
RENAL and URINARY DISORDERS 
 Urinary disorders  
 Bladder spasm  
 Urinary retention  
REPRODUCTIVE SYSTEM and BREAST DISORDERS 
Hot flashes/sweats Gynecomastia  
Testicular atrophy Breast Tenderness  
 Lactation  
 Testicular Pain  
 Impotence  
 Libido decreased  
 Nocturia  
RESPIRATORY, THORACIC and MEDIASTINAL DISORDERS 
 Emphysema  
 E pistaxis  
 Pleural Effusion  
 Pulmonary Edema  
 Dyspnea  
 Cough  
SKIN and SUBCUTANEOUS  TISSUE DISORDERS 
 Acne  
 Alopecia  
 Bruising  
 Cellulitis  
 Pruritus  
 Rash  
 Hirsutism  
VASCULAR DISORDERS 
 Varicose Veins  
 Deep Thrombophlebitis  
 
 <1%, post marketing, and/or cas e reports: Abdominal pain, anap hylactic/anaphylactoid 
reactions, asthmatic reactions, bone density decr eased, coronar y artery disease, diabetes; 
fibromyalgia-like symptoms; flushing, hemoptysis, hepatic dysfu nction, hypokalemia, 
hypoproteinemia,  injection  site   induration/abscess,  liver  injury, myocardial infarction, pelvic 
fibrosis, penile swelling, peripheral neuropathy, photosensitiv ity; pituitary apoplexy; prostate pain, 
pulmonary embolism, pulmonary inf iltrate, seizure, spinal fract ure/paralysis, stroke suicidal 
ideation/attempt (rare), tenosynovi tis-like symptoms, thrombocy topenia,   transient   ischemic   
attack,   uric   acid  increased, urticaria, WBC decreased/incr eased. 
  The FDA issued a safety communication in October 2010 based on  their ongoing safety review 
35 
 of LHRH agonists. The safety co mmunication discusses the potential for an increased risk of 
diabetes and cardiovascular disease (myocardial infarction, sud den cardiac death, stroke) 
associated with these agents. The risk is thought to be low in men receiving LHRH agonists for 
prostate cancer. In this trial, LHRH agonists are being adminis tered for a short period of time. 
FDA recommendations include management of cardiovascular risk f actors according to current 
standards of practice.   DOSING & ADMINISTRATION 
1. Dosing – See Treatment Plan 
2. Leuprolide is administered intram uscular (Lupron Depot®). Injec tion sites should be 
varied periodically. 
 STORAGE & STABILITY: Refer to t he current FDA-approved package insert for storage, 
stability and special  handling information. 
  HOW SUPPLIED 
1. Leuprolide acetate, 7.5 mg (1 month), 22.5 mg (3 months), 30 mg  (4 months) or 45 mg (6 
months) depot formulation kit with accompanying diluent. The pr efilled dual-chamber 
syringe contains lyophilized microspheres of leuprolide acetate incorporated in a biodegradable lac tic acid polymer. 
2. Commercial supply of Leuprolide will be used. Refer to the curr ent FDA-approved 
package insert for add itional information.  
 
 
4. PATIENT SELECTION 
 
In calculating days of tests and measurements, the day a test o r measurement is done is considered 
Day 0. Therefore, if a test is done on a Monday, the Monday 4 w eeks later would be considered 
Day 28. This allows for efficient patient scheduling without ex ceeding the guidelines. If Day 28, 
42, or 56 falls on a weekend or holid ay, the limit may be exten ded to the next working day. 
 
4.1  Inclusion Criteria  
 At registration all patients must: 
 Have pathologic diagnosi s of prostate cancer. 
 
 Have hormone-sensitive metastatic  disease (M1) as evidenced by soft tissue and/or 
bony metastases.  
 
 Patients may either be untreated for their newly diagnosed metastatic disease (preferred 
as much as possible) or have started androgen deprivation therapy.  Patients who have 
started androgen depriv ation therapy for the treatment of their newly diagnosed metastatic 
disease are eligible as long as t he duration of treatment is le ss than or equal to 2 weeks (14 
days)
 prior to registration. The start date of androgen deprivation is considered the day the 
patient first received an injection of a LHRH agonist/antagonis t (or orchiectomy), not the 
date when an oral antiandrogen started.  
36 
  Patients must have a minimum PSA ≥ 5 ng/mL within 60 days of re gistration or prior 
to the initiation of androgen depr ivation for patients who have  started androgen deprivation 
therapy. 
 
 Agree to undergo a biopsy of at least one metastatic site for R B status evaluation 
(Please refer to Appendices B and C for specific procedures ).  Adequate metastatic tissue 
from prior biopsy/resection ca n be used if available in lieu of  a biopsy.   
 
 ECOG performance status of 0-2.   
  Age ≥ 18 years.   
  Patients may have received prior neoadjuvant and/or adjuvant ho rmonal therapy for 
non-metastatic disease including in combination with salvage ra diation therapy for PSA 
relapse, but it must not have lasted for more than 36 months. A t least 12 months must have 
elapsed since completion of androgen deprivation therapy in the  neoadjuvant and/or 
adjuvant setting.  
 
 Patients must have adequate orga n and marrow function as define d below obtained within 14 
days prior to registration: 
WBC  3,000/µl 
ANC  1,500/µl 
Platelet count  100,000/µl 
Serum Creatinine 1.5 x the institutional upper limits of 
normal or corrected creatinine clearance 
of  ≥ 50 mg/ml/hr/1.73 m2 BSA 
Bilirubin within the institutional limits of normal 
SGOT (AST) SGPT (ALT)  2 x upper limits of normal 
    2 x upper limits of normal 
 
 Patients must be able to take oral medication without crushing,  dissolving or chewing 
tablets. 
 
 Patients may have received prior radiation therapy or surgery. However, at least 14 
days must have elapsed since completion of radiation therapy or  surgery and patient 
must have only grade 2 or less adverse effects at the time of r egistration.  
 
 Patients must agree to use highly effective contraception (deta ils outlined in the consent 
form) during treatment and for a period of 90 days after ending  t r e a t m e n t  w i t h  
palbociclib.  
  Ability to understand and the willingness to sign a written inf ormed consent document 
that is approved by an institutional review board. 
 
4.2 Exclusion Criteria 
 
37 
  Patients who have received androgen deprivation therapy for gre ater than 14 days 
(LHRH-agonist or antagonist) for the treatment of their newly d iagnosed metastatic 
disease prior to enrollment ar e not eligible for this study. 
 
 Patients who are currently being treated with strong CYP3A4 inh ibitors (e.g., 
amprenavir, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, 
mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, r itonavir, saquinavir, 
telaprevir, telithromycin, verapamil, voriconazole, and grapefr uit) or strong CYP3A 
inducers (e.g., carbamazepine, felbamate, nevirapine, phenobarb ital, phenytoin, 
primidone, rifabutin, rifampin, rifapentin and St. John’s wort)  must either discontinue 
these drugs or are ineligible. 
 
 Grade 3 QTc prolongation (QTc  >500 msec on two separate ECGs).  
  Patients with known brain metastases should be excluded from th is clinical trial 
because of their poor prognosis and because they often develop progressive neurologic 
dysfunction that would confound the evaluation of neurologic an d other adverse events. 
  Uncontrolled intercurrent illness including, but not limited to , ongoing or active 
infection, symptomatic congestive heart failure (New York Heart  Association Class III 
and IV heart failure), unstable angina pectoris, cardiac arrhyt hmia, or psychiatric 
illness/social situations that would limit compliance with stud y requirements. 
 
 Patients with a "currently active" second malignancy other than  non-melanoma skin 
cancers are not eligible. Patients are not considered to have a  "currently active" 
malignancy if they have completed all therapy and are now considered without 
evidence of disease for 1 year.  
 
 HIV-positive patients on combination antiretroviral therapy are  ineligible because of 
the potential for pharmacokinetic interactions with palbociclib .  In addition, these 
patients are at increased risk of  lethal infections when treate d with marrow-suppressive 
therapy.   
  
38 
 4.3 Inclusion of Women and Minorities 
This study applies only to men. All races and ethnic groups are  eligible for this trial. 
The anticipated accrual in the ethnicity/race categories is sho wn in the table below.  
 
   Ethnic Category Males Total 
Hispanic or Latino 6 6 
Not Hispanic or Latino 54 54 
Total Ethnic 60 60 
   Racial Category   
American Indian or Alaskan Native 1 1 
Asian 2 2 
Black or African American 10 10 
Native Hawaiian or other Pacific Islander 0 0 
White  47 47 
Racial Category: Total of all Subjects 60 60 
 
5. REGISTRATION  
 
5.1    Pretreatment Evaluation 
 
Clinical: (completed within 14 w orking days prior to registrati on) 
 Complete history to include all past or current medical conditi ons, current medications, 
date of diagnosis, and pathologi cal confirmation of prostate ca rcinoma. 
 Physical Examination including he ight, weight, ECOG Performance  Status and EKG. 
             Laboratory: (completed with in 14 working days prior to registration) 
 Hematology: Complete blood count,  differential and platelet cou nt. 
 Comprehensive Panel: sodium, potassium, chloride, bicarbonate, BUN, creatinine, 
glucose, calcium, AST, ALT, alkaline phosphatase, phosphorous, total bilirubin, 
albumin, total protein and magnesium. 
 PSA. 
       Imaging and Diagnostic Studies: (completed within 6 weeks prior to registration or prior to initiation of androgen deprivation for patients who have alr eady started ADT prior to 
registration) 
 Chest radiograph (CT or MRI  thorax also acceptable) 
 CT or MRI of the abdomen/pelvis 
 Radionuclide Bone Scan 
 
5.2    Subject Screening and Registration Procedure  
 
Patient registration and randomi zation for this trial will be centrally managed by the 
Clinical Trials Office of The U niversity of Michigan Comprehens ive Cancer Center 
(UMCC) as described below: 
 
 A potential study subject who has b een screened for the trial a nd who has signed 
39 
 the Informed Consent document will be initially documented by t he participating 
site on the Screening and Enro llment Log provided by the Clinic al Trials Office. 
 
 It is the responsibil ity of the local site  investigator to dete rmine patient eligibility 
prior to submitting patient registration request to the multi-s ite Coordinator of the 
UMCC Clinical Trials Office.  Aft er patient eligibility has bee n determined, a 
copy of the completed Eligibility W orksheet together with all t he pertinent de-
identified source documents will be submitted by the requesting site to the 
Clinical Trials Office, either by fax or by email to : 
 
Ben Wright, CAPM CCRP Cancer Center Clinical Trials Office North Campus Research Complex (NCRC) Building 300 Main Ann Arbor, MI 48109-2800 Phone: 734-763-0722 Fax: 734-232-0744 Email: bdwright@med.umich.edu 
 Kathleen Granlund, CCRP Cancer Center Clinical Trials Office North Campus Research Complex (NCRC) Building 300 Main Ann Arbor, MI 48109-2800 Telephone: 734-936-0563 Fax: 734-232-0744 Email: kemarsh@med.umich.edu 
 
 The Multi-Site Coordinator of t he Clinical Trials Office, who a cts as the registrar, 
will review the submitted documents and process the registratio n. Sites should 
inform the Multi-Site Coordina tor of a potential registration b y 5 p.m. on the day 
prior to registration.  Same da y registrations cannot be guaran teed.   
 
 An email will be sent by the registrar to the requesting site registrar to confirm 
patient registration and randomi zation and to provide the study  identification 
number and randomization number t hat has been assigned to the p atient. In 
addition, a copy of the completed E ligibility Worksheet signed and dated by the 
registrar, will be emailed bac k to the requesting site registra r. 
 
 Patients found to be ineligible fo r participation after being c onsented will be 
considered screen failures, and documented as such in the Scree ning and 
Enrollment Log. These patients will not have study identificati on number 
assigned to them, and will not  receive study treatment.  
 
  5.3       Biopsy and Randomization 
40 
  
5.3.1 Following registration, patient  biopsies must be performed within 10 working days 
(unless archival biopsy tissue is already available from a meta static site in which case it 
must be provided within 10 working days).   
 5.3.2 Issues that would cause treatment delays should be discus sed with the Principal 
Investigator Dr. Hussain.  If a patient is eligible for treatment, protocol therapy must start within 10 working days from the biopsy date or receipt of archi val tissue.   
 5.3.3 Biopsy tissue should be processed and shipped to the Michigan Center for Translational Pathology. The coor dinator for the Michigan Cente r for Translational 
Pathology will inform the registr ar as well as the participatin g site whether the patient has 
adequate tissue for RB analysis.  5.3.4 If the patient has adequate tissue which stains positivel y for RB, the study pathologist 
will also inform the statistician , Stephanie Daignault-Newton a t 734-647-3271 or 
sfaruzzi@umich.edu and randomization will be perfor med.  (See Section 6, Treatmen t 
Plan).  Randomized patients shoul d begin protocol treatment wit hin 7 working days from 
randomization.  Issues that would cause treatment delays should  be discussed with the 
Principal Investigator.   
 5.3.5 If the patient does not have adequate tissue for RB analy sis, he will be removed from 
protocol unless the patient is willing to undergo another biops y. Repeat biopsy will need 
to be done within 10 working days of initial biopsy as long as patient still fulfills other 
eligibility criteria.  No study la bs are needed but safety labs  can be done as deemed 
necessary by the managing oncologist.  Patients will be randomi zed once adequate tissue 
is evaluated and positive for RB staining.  5.3.6 If a patient does not receive protocol therapy following registration, the patient’s 
registration on the study may be canceled. The registrar should be notified of cancellations as soon as possible.   5.3.7 If available, diagnostic tissu e from prostatectomy or pri or biopsy will also be 
requested for corre lative studies.   
 If primary prostatectomy is available (preferred): The block with the highest volume of representative tumor histology from the index focus should be s ent. Up to 12 x 5 micron 
sections will be taken from the block as needed. If blocks cann ot be sent, a total of 16 
x 4-5 micron unstained, unbaked s ections on glass slides (charg ed or uncharged) from 
the block with the highest volume  of representative tumor histo logy should be sent. 
 If primary biopsy is available: Three blocks with the highest volume of representative 
tumor histology should be sent. A total of 9 x 10um sections wi ll be taken from one or 
more blocks as needed without exhausting the blocks. If less th an three blocks have 
cancer, then all blocks with cancer should be sent. If blocks c annot be sent, a total of 
15 x 4-5 micron unstained sections  on glass slides from one or more blocks with the 
highest volume of representative tumor histology should be sent . 
41 
   If unstained sections are sent, they should be labeled with th e block number/letter. If 
less than three blocks have cancer, then as many unstained 4-5 micron sections (up to 
15) as can be cut from blocks w ith cancer without exhaustion sh ould be sent.   
  
5.4       Data Management 
All information will be recorded  locally and entered into Case Report Forms (CRFs) on  
the web-based Velos data management system of the University of  Michigan. Online 
access will be provided to each site by the Coordinating Center .  
 
CRFs will be reviewed and source  verified by the MSC during ann ual monitoring visits  
and prior to and between visits. D iscrepant, unusual and incomp lete data will be queried  
by the MSC. The investigator or study coordinator will be respo nsible for providing 
resolutions to the data queries, as appropriate. The investigator must ensure that all data 
queries are dealt with promptly.   The data submission schedule is as follows:  
 At the time of registration   
o Subject entry into Velos 
o Subject Status 
o Demographics 
 During study participation 
o All data should be entered on line within 10 working days of dat a 
acquisition. Information on dose limiting toxicity events must be entered 
within one working day. Information on Serious Adverse Events m ust be 
entered within the reporting timeframe specified in Section 8 o f the 
protocol.  
  Long term data will be collect ed periodically either by chart r eview or by contacting the 
patients. All study information should be r ecorded in an appropriate sour ce document (e.g. clinic 
chart).  
  
6. STRATIFICATION, RANDOMI ZATION AND TREATMENT PLAN  
       
6.1        Stratification and Randomization    
 Stratification:  All patients will be stratified by ADT treatment pre-registra tion for M1 
disease (yes versus no) and disease extent defined as limited ( disease confined to the spine, 
pelvic bones and or lymph nodes)  or extensive (ribs, long bones , or visceral organs with or 
without other sites). 
 
Randomization:  All eligible patients with RB-positive tumor will be randomly  assigned 
(1:2) to receive ADT (LHRH agonist + biclutamide) alone (ARM 1)  or ADT plus 
palbociclib (ARM 2).    
 
42 
 6.2       Agent Administration  
 Patients will only be eligible for protocol therapy if the meta static disease biopsy 
or prior metastatic disease biops y/resection tissue has adequat e tumor tissue for RB 
analysis and the tissue is RB positive.  
 
 Treatment will be administered on an outpatient basis.  Reporte d adverse events 
and potential risks are described in Section 3.  Appropriate dose modifications are 
described in Section 7. No inves tigational or commercial agents  or therapies other 
than those described below may be administered with the intent to treat the patient's 
malignancy. 
 
 In both Arms androgen deprivation therapy should be administere d after the biopsy 
is done, unless androgen deprivati on was started prior to regis tration. 
 
 In Arm 2 palbociclib  should be administered post randomization  as soon as agent 
is available (within 7 working days  from randomization in case  time for drug 
shipment is needed)  
 
 
  
 
 
    
  
           
   
*LHRH-analogue: Either gosere lin or leuprolide dosing to be determined at discretion of 
treating physician. 
** Palbociclib : 125 mg to be taken daily for 21 days with 7 days off during a  28 day cycle.  
Drug should be taken with food.   Arm 1 Treatment 
Agent Dose Route Schedule Cycle Length 
LHRH-analogue*(any formulation)    Continuously 
 
Bicalutamide 50 mg Oral Daily  
Continuously 4 weeks 
Arm 2 Treatment 
Agent Dose Route Schedule Cycle Length 
LHRH- analogue*(any formulation)    
 Continuously 
 
Bicalutamide 50 mg Oral Da ily Continuously 4 weeks  
Palbociclib** 125 mg Oral Daily, 
Days 1-21 of a 28 day cycle.   28 days (4 weeks: 3 weeks of therapy + 1 week off) 
43 
  For patients who have not started ADT D1 is the day palbociclib   + LHRH-a or 
LHRH-a therapy (based on randomization) is started.    
 For patients who have started ADT D1 will be the day of randomization.  “D1 
exam, labs and correlative studies” must be done within 7 worki ng days from 
randomization.  All subsequent labs, imaging and endpoints will  be counted 
from this day.  
 For subsequent cycles, the formal “Day 1” of each cycle is defi ned as the day 
that Palbociclib dosing resumes. 
 Patients will continue treatment until disease progression or o ther reason for   
discontinuation of protocol treatment. 
 Patient Diary: Bicalutamide and palbociclib compliance will be recorded on the 
Patient Diary (see Appendix G a nd H). Institutional staff will review and ascertain 
patient adherence with protocol treatment. If a dose of either agent is missed, 
patients are to take the normal dose on the following day.  If more than one daily 
dose is missed, the study doctor  or study team must be informed . 
 General rules for palboc iclib administration: 
o Palbociclib should be taken with food. 
o Palbociclib capsules should be swallowed whole (do NOT chew, cr ush or 
open them prior to swallowing). 
o No capsule should be ingested if it is broken, cracked, or othe rwise not 
intact. 
o Patients should be encouraged to take their dose at approximate ly the same 
time each day. 
o Patients who miss a day’s dose entirely must be instructed NOT to “make 
it up” the next day. 
o Patients who vomit any time after taking a dose must be instructed NOT to “make it up,” and to resume treatme nt the next day as prescribed. 
o Patients who inadvertently take 1 extra dose during a day must be 
instructed to skip t he next day’s dose.  
 6.3  General Concomitant Medicat ion, Treatment and Supportive C are Guidelines  
 
 Patients may continue on a daily Multi-Vitamin, calcium and Vit amin D, but all other 
herbal, alternative and food supplements (i.e. PC-Spes, Saw Pal metto, St John’s Wort, 
etc.) must be discontinued before registration.    
 Patients may not receive any othe r investigational anticancer a gents (besides  stu
 dy drug 
and ADT) for this stage of disease. Patients may not undergo co ncurrent radiation 
therapy.  
 Other excluded treatments incl ude chemotherapy, immunotherapy, and 
radiopharmaceuticals or any other therapy intended to treat prostate cancer. 
 
 In case participants develop nausea/vomiting/diarrhea or myelos uppression, supportive 
medications will be allowed according to institutional standard s.  
 
44 
  Because there is a potential for interaction of palbociclib wit h other concomitantly 
administered drugs through the cytochrome P450 system, the medi cal record must 
capture the concurrent use of all other drugs, over-the-counter  medications, or 
alternative therapies. The Princ ipal Investigator (Dr. Hussain)  should be alerted if the 
patient is taking any agent known to affect or with the potenti al to affect selected 
CYP450 isoenzymes and the agent should be discontinued or situa tion discussed with 
her.   
 
 Drugs that Inhibit or Induce CYP3A4 Enzymes  (non-comprehensive list):  
 
Patients are not eligible if they are taking one of the agents below.  Similarly if any of 
these agents has to be started for patients randomized to the p albociclib arm then 
patients must come off treatment .  Patients will be followed fo r progression. 
 
Strong CYP3A4 inhibitors: amprenavir, fosamprenavir, indinavir,  itraconazole, 
ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, ne lfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithromycin,  verapamil, 
voriconazole, and grapefruit 
 Strong CYP3A4  inducers: carbamazepine, felbamate, nevirapine, phenobarbital, 
phenytoin, primidone, rifabutin, rifampin, rifapentin and St. John’s wort. 
 
 Transfusions and hematologic growth factors are allowed in acco rdance with 
institutional guidelines. 
 
6.4  Duration of Therapy  
 
In the absence of treatment delays due to adverse event(s), tre atment may continue until 
one of the following c riteria applies: 
 
 Disease progression (d efined in section 11), 
 
 Intercurrent illness that prevents further administration of tr eatment, 
 
 Unacceptable adverse event(s) (see sections 3 and 8),  
 
 Therapy delay for more than 4 weeks, 
 
 Patient decides to withdraw from the study, 
 
 General or specific changes in the patient's condition render t he patient 
unacceptable for further treatment in the judgment of the inves tigator. 
  
45 
 6.5     Duration of Follow Up  
 
 Patients removed from study treatment for progression will be f ollowed for 4 weeks or 
resolution/stabilization of any t herapy related a dverse events.     
 
 Once off study treatment for any reason other than progression,  follow-up visits will be 
done every 12 weeks.  These visits will include H&P and laborat ory assessment 
(CBCPD, Chemistry, PSA).  Imaging will be done q 24 weeks.  Clinical, Laboratory 
and imaging evaluations will be done for 2 years or until progr ession, whichever comes 
first.  
 
 Patients removed from study treatment for unacceptable adverse event(s) may be 
followed more frequently than every 12 weeks per the investigator’s discretion until resolution or stabilizatio n of the adverse event. 
   
7. DOSING DELAYS/DOSE MODIFICATIONS 
 
 This study will utilize the CTCAE (NCI Common Terminology Crite ria for Adverse 
Events) Version 4.0 for toxicity and Serious Adverse Event repo rting.  A copy of the 
CTCAE Version 4.0 can be downloaded from the CTEP home page 
(http://ctep.cancer.gov).  All appropriate treatment areas shou ld have access to a copy 
of the CTCAE Version 4.0.  
 Toxicities (including suspected reactions) that meet the seriou s reporting criteria as 
outlined in section 8.0 of the protocol must be reported to the  Coordinating Center Lead 
PI and Multi-site Project Manager  and to the IRB per local IRB requirements. 
 
 For treatment or dose modificat ion related questions, please co ntact Dr. Maha 
Hussain at 312-695-6180 or maha.hussain@northwestern.edu  or cto-
multisite@med.umich.edu .  
  If a patient experiences several adverse events and there are c onflicting 
recommendations, the investig ator should use the recommended do se adjustment that 
reduces the dose to the lowest level. 
 
 Combined ADT will be require d throughout duration of the study.   
 
 If patient desires to discontinue ADT, he will be removed from study 
treatment.  
 
 If patient develops serious advers e event felt to be related to  bicalutamide 
(e.g., liver toxicity) then bical utamide can be discontinued wh ile continuing 
LHRH agonist/antagonist pl us or minus palbociclib. 
 
  
46 
 7.1 Palbociclib Dose Reductions: 
 
In the event of significant treatment-related toxicity, palbociclib dosing may be interrupted or delayed and/or reduced as descri bed below. In the event of mult iple toxicities, dose 
modification should be based on t he worst toxicity observed.  
Patients are to be instructed to notify Investigators at the fi rst occurrence of any adverse sign 
or symptom.  
            Dose levels are defined below: 
 
Dose Level Palbociclib 
0 125 mg daily 
-1 100 mg daily 
-2 75 mg daily 
 
o Dose modifications may occur in three ways: 
 Within a cycle: dosing interruption until adequate recovery fol lowed by 
dose reduction, if required. 
 Between cycles: next cycle administration may be delayed due to  persisting 
toxicity when a new cycle is due to start. 
 At start of the new cycle: dose reduction may be required in a subsequent cycle based on toxicity experi enced in the previous cycle. 
 
7.1.1 Palbociclib Dose Modification and Management:  
  
Table 1. Palbociclib Dose Modif ication and Management – Hematol ogic Toxicities
a 
CTCAE Grade Dose Modifications 
Grade 1 or 2 No dose adjustment is required. 
Grade 3  Day 1 of cycle: Withhold palbociclib, repeat complete blood count monitoring wi thin 
1 week.  
 If recovered to Grade ≤2, resume at the same dose . 
 If Grade 3, hold initiation of next  cycle until recovery to 
Grade ≤2. Resume at the same dose . 
 If Grade 4, hold initiation of next  cycle until recovery to 
Grade ≤2. Resume at the next lower dose. 
 Day 14 of first 2 cycles: Continue palbociclib at current  dose. Repeat complete blood cou nt on 
Day 21. 
 If Grade 3 on Day 21, start subsequent cycles at the same dose . 
 If Grade 4 on Day 21, start subsequent cycles at the next lower 
dose. 
 Consider dose reduction in cases of prolonged (>1 week) recovery from 
47 
 Table 1. Palbociclib Dose Modif ication and Management – Hematol ogic Toxicitiesa 
CTCAE Grade Dose Modifications 
Grade 3 neutropenia or recurrent Grade 3 neutropenia in subsequ ent 
cycles. 
Grade 3 neutropenia 
with fever ≥38.5 ºC and/or infection Withhold palbociclib until recovery to Grade ≤2. 
Resume at the next lower dose . 
Grade 4 
 Withhold palbociclib until recovery to Grade ≤2. 
Resume at the next lower dose . 
Grading according to CTCAE 4.0 (Grade 1: ANC < LLN - 1500/mm3; Grade 2: ANC 1000 - <1500/mm3; 
Grade 3: ANC 500 - <1000/mm3; Grade 4: ANC <500/mm3). 
ANC=absolute neutrophil count; CTCAE=Common Terminology Criteri a for Adverse Events; LLN=lower limit 
of normal. 
a Table applies to all hematologic adverse reactions except lymp hopenia (unless associat ed with clinical events, 
e.g., opportunistic infections). 
 
Table 2. Palbociclib Dose Modif ication and Management – Non-Hematologic Toxicities 
CTCAE Grade  Dose Modifications  
Grade 1 or 2 No dose adjustment is required. 
Grade ≥3 non-hematologic toxicity (if persisting despite medical treatment) Withhold until symptoms resolve to: 
 Grade ≤1; 
 Grade ≤2 (if not considered a safety risk 
for the patient) 
Resume at the next lower dose . 
Grading according to CTCAE 4.0. 
CTCAE=Common Terminology Criteria for Adverse Events. 
 
 
7.1.3. A dose reduction of 1 level will be pursued for all Grade 4 t oxicities and also for any Grade 
3 toxicity that in the opinion of the investigator will potenti ally impact the safety of the 
participant.  Dose reductions bas ed on the above criteria can o ccur at the start of a new 
cycle or at the time of retreatment. 
 
o The dose of palbociclib will not be re-escalated once a dose reduction has occurred.  
 
o Asymptomatic laboratory abnormalities would not be considered a  serious adverse 
event unless the treating physic ian believes it may potentially  impact the 
participant’s safety.  
 
o If palbociclib is delayed more than 4 weeks for any reason, or if a dose reduc tion 
below 75 mg daily is required, patients will be removed from pr otocol treatment. 
 
o Doses should be held until toxic ity resolution. Appropriate fol low up assessments, 
as defined by the investigator, should be undertaken until adeq uate recovery occurs.  
 
 
o Criteria required before treatment can resume are described in the Retreatment 
48 
 criteria section above. 
 
o Depending on when the adverse event resolved, a treatment inter ruption may lead 
to the patient missing all subsequent planned doses within that  same cycle or even 
to delay in the initiation of the subsequent cycle. 
 
o If the adverse event that led to the treatment interruption rec overs within the same 
cycle, then re-dosing in that cycle is allowed. Doses omitted f or toxicity are not 
replaced within the same cycle.  
 
o The need for a dose reduction at the time of treatment resumpti on should be based 
on the criteria defined in the Dose Reductions Section unless a n alternative plan is 
expressly agreed upon between the treating physician and the PI .  
 
o If a dose reduction is applied in  the same cycle, the patient w ill need to return to 
the clinic to rece ive new drug supply. 
  
7.2  Bicalutamide Dose Hold  
 
There are no dose reducti ons for Bicalutamide.    
 
7.2.1. Diarrhea: The major toxic effect of bicalutamide is moderate diarrhea which is rarely severe (exclusion of other causes of diarrhea should be considered in severe cases). The dose 
modifications for this will be as follows. 
 Grade 2 diarrhea, treat symptoma tically with ant i-diarrhea drug s. 
 Grade 2 diarrhea unresponsive to s ymptomatic treatment or Grade  3 or 4 diarrhea - 
discontinue bicalutamide until complete recovery. 
Further tests are up to discret ion of treating physician. Resta rt treatment as per protocol 
when diarrhea resolves to ≤ Grade 1.   
 7.2.2. Abnormal Liver Function Tests (SGOT/AST, SGPT/ALT, Bilirubin)  
Grade 3 or greater toxicity - St op bicalutamide. Hepatitis scre ening (A, B, C) should be 
done in all cases of abnormal LFTs  which could be consistent wi th infectious hepatitis. 
To assess return to normal, abnormal liver function tests shoul d be done weekly or more 
frequently, as per the discre tion of the treating physician.   Bicalutamide may be restarted 
after LFTs normalize (< or = Grade 1) if the event is deemed no t related to Bicalutamide.  
 7.2.3. Patients may complain of flatu lence, bloating and mild "gas pains" which should 
not result in changes in treatme nt. Symptomatic treatment shoul d be employed with 
antacids, simethicone, etc.   7.2.4. If patient develops serious adverse event felt to be related to bicalutamide then 
bicalutamide can be discontinued while continuing LHRH agonist/  
antagonist plus or minus palbociclib  (based on arm). 
49 
  
7.2.5. For any other Grade 3-4 adverse ev ents which the investigator  believes to be 
related to bicalutamide and is clinically significant stop bica lutamide.   
 7.2.6 Asymptomatic Grade 3 or 4 labor atory findings, which are not c onsidered clinically 
significant may not require dose  hold. The decision to hold the  dose should be based on 
the investigator’s clinical judgment. 
 
 
8. ADVERSE EVENTS  
    
8.1 Adverse Events and Potential Risks Related to Palbociclib (see section 3.1). 
 
 For the most recent safety update, please refer to the current Investigator’s Brochure.  
 For contraindications, interactio ns with other medications and known adverse reactions 
related to palbociclib p lease see section 3.1. 
 
8.2 Adverse Event Reporting Requirements 
 
8.2.1  Adverse event (AE) monitoring a nd reporting is a routine part  of every 
clinical trial and is done to ensure the safety of subjects enrolled in the studies as 
well as those who will enroll in future studies using similar a gents. Data on 
adverse events will be collected from the time of the initial s tudy treatment 
administration through 30 days aft er the last dose of study tre atment. Any serious 
adverse event that occurs more than 30 days after the last stud y treatment and is 
considered related to the study t reatment must also be reported . Serious Adverse 
Events (SAEs) will continue to be followed until: 
 Resolution or the symptoms or signs that constitute the serious  adverse 
event return to baseline; 
 There is satisfactory explanati on other than the study treatmen t for the 
changes observed; or  
 Death. 
8.2.2   The investigator is responsib le for the detection, documenta tion, grading 
and assignment of attribution of events meeting the criteria an d definition of an 
AE or SAE. The definitions of A Es and SAEs are given below. It is the 
responsibility of the Protocol pr incipal investigator and site investigator to ensure 
that all staff involved in the trial are familiar with the cont ent of this section. 
8.2.3 Any medical condition or labor atory abnormality with an onset date before 
initial study treatment admini stration is considered to be pre-existing in nature. 
Any known pre-existing conditions  that are ongoing at time of s tudy entry should 
be considered medical history. 
8.2.4  All events meeting the criteri a and definition of an AE or SA E, as defined 
in Section 8.3, occurring from the  initial study treatment admi nistration through 
50 
 30 days following the last dose of  the study treatment must be recorded as an 
adverse event in the patient’s  source documents and on the CRF regardless of 
frequency, severity (grade) or a ssessed relationship to the stu dy treatment.  
8.2.5   In addition to new events, any increase in the frequency or severity (i.e., 
toxicity grade) of a pre-existing condition that occurs after t he patient begins 
study treatment is also considered an adverse event. 
8.3 Definitions 
8.3.1 Adverse Event 
 An adverse event (AE) is any untoward medical occurrence in a patient receiving 
study treatment and which does not necessarily have a causal re lationship with 
this treatment. An AE can be a ny unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally as sociated with the 
use of an experimental intervention, whether or not related to the intervention.  
 
Diagnostic and therapeutic non-invasive and invasive (i.e., surgical) procedures 
will not be reported as adverse events. However, the medical condition for which 
the procedure was performed must be reported if it meets the definition of an 
adverse event unless it is a pre-existing (p rior to protocol treatment) condition. 
 
 Symptoms of the original or tar geted disease will be considered adverse events. 
The following symptoms are indi cative of underlying disease (Metastatic Prostate 
Cancer) and will be reported as adverse events. Attribution to underlying disease 
versus therapy mu st be provided:  
 
o Bone Pain o Urinary Obstruction o Spinal Cord Compression o Fractures  
 Abnormal laboratory values or test results constitute adverse events if they 
induce clinical signs or symptoms or re quire therapy. They are to be captured 
under the signs, symptoms or diagnoses associated with them.  
 
 Hy’s	Law	Cases.		Cases	of	potential 	drug‐induced	liver	injury	as	assessed	by	
laboratory 	test	values	(“Hy’s 	Law	Cases”)	are	
 also	reportable	to 	Pfizer.		If	a	
Study	subject	develops 	abnormal 	values	in	aspartate 	transaminase 	(AST)	or	
alanine	transaminase 	or	both,	concurrent 	with	abnormal 	elevations 	in	total	
bilirubin	and	no	other	known	cause	of	liver	injury,	that 	event	would	be 	
classified 	as	a	Hy’s	Law	Case.	This	reporting 	requirement 	is	 further	
explained 	in	the	training	material 	provided 	by	Pfizer‐.		As	used	in	this	
Agreement, 	the	term	SAE	will	be	understood 	to	also	include	Hy’s	Law	
Cases.”	
51 
 8.3.2 Serious Adverse Event 
An adverse event is considered “serious” if, in the view of eit her the Site 
Investigator or the protocol P I it results in any of the follow ing outcomes: 
  
o Death 
If death results from (progression of) the disease, the disease  should be 
reported as event (SAE) itself. 
 
o A life-threatening adverse event 
An adverse even is considered ‘ life-threatening’ if, in the vie w of 
either the investigator [or sponsor], its occurrence places the  patient or 
subject at immediate risk of death. It does not include an adve rse event 
that, had it occurred in a more se vere form, might have caused death.  
 
o Inpatient hospitalization or prolongation of existing hospitali zation for 
> 24 hours. 
 
o A persistent or significant incap acity or substantial disruptio n of the 
ability to conduct normal life functions 
 
o A congenital anomaly/birth defect 
 
o Important medical event 
Any event that may not result in death, be life-threatening, or  require 
hospitalization may be considered serious when, based upon 
appropriate medical judgment, the y may jeopardize the patient a nd 
may require medical or surgical intervention to prevent one of the 
outcomes listed in this  definition of “Serious Adverse Event”. 
Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in a n emergency room or at home; 
convulsions that do not result i n inpatient hospitalization or the 
development of drug dependency or drug abuse. 
 
o Previously planned (prior to sig ning the informed consent form)  
surgeries should not be reported as SAEs unless the underlying 
medical condition has worsened dur ing the course of the study. 
Preplanned hospitalizations or procedures for preexisting condi tions 
that are already recorded in the pa tient’s medical history at t he time of 
study enrollment should not be consid ered SAEs. Hospitalization  or 
prolongation of hospitalization w ithout a precipitating clinica l AE (for 
example, for the administrati on of study therapy or other proto col-
required procedure) should not be c onsidered SAEs. However, if the 
preexisting condition worsened dur ing the course of the study, it 
should be reported as an SAE.  
o Exposure During Pregnancy: 
52 
 Paternal exposure must be reported if a male has been exposed ( e.g., 
due to treatment or environmenta l exposure) to the investigatio nal 
product prior to or around the t ime of conception of his child and/or is 
exposed during the partner’s pregnancy. 
 
8.3.3 Expected Adverse Events 
An adverse event (AE) is considered “expected” if: 
 For approved and marketed drugs or devices, those adverse events 
are described in the approve d Package Insert (Label).  
 For investigational new drugs, t hose adverse events are describ ed 
in the FDA Investigator’s Brochure.  
 In clinical research studies , information on expected adverse 
events is also summarized in the  protocol and in the consent 
document.  See section 3.1 for the  list of expected adverse eve nts 
related to the drug under study. 
8.3.4 Unexpected Adverse Event 
An adverse event (AE) is consid ered “unexpected” if it is not d escribed in 
the Package Insert, Investigator’s Brochure, in published medic al 
literature, in the protocol, or  in the informed consent documen t.  
8.4 Adverse Event Characteristics 
8.4.1 CTCAE Term 
(AE description) and grade: The descriptions and grading scales  found in 
the NCI Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0 will be utilized for AE reporting. All appropriate treatment 
areas should have access to a copy of the CTCAE version 4.0. A copy of 
the CTCAE version 4.0 can be down loaded from the CTEP web site . 
(http://ctep.cancer.gov ) 
 
           8.4.2   Attribution of the AE 
The investigator or co-investig ator is responsible for assignment of 
attribution. 
Definite – The AE is clearly related  to the study treatment. 
Probable – The AE is likely related to the study treatment 
Possible – The AE may be related  to the study treatment. 
Unlikely – The AE is doubtfully related  to the study treatment. 
Unrelated – The AE is clearly NOT related to the study treatment. 
8.5 Serious Adverse Event Reporting Guidelines 
8.5.1 The PI and the Coordinating Cen ter must be notified within 24 h ours of first 
awareness of the event (immediatel y if the event is fatal or li fe-threatening) 
meeting the criteria and definition of a serious adverse event,  regardless of 
53 
 attribution, occurring  from after the first dose  of Pfizer Product through 30 
days after the last administ ration of the Pfizer Product.  In a ddition, SAEs 
should be submitted any time after the administration of the la st dose of the 
Pfizer Product if the Investigat or suspects a causal relationsh ip between the 
Pfizer Product and the SAE.  
8.5.2 All serious adverse events must be reported to t he Coordinating  Center 
within 24 hours of first awarene ss of the event.  Events should be reported 
using the Medwatch 3500A form.  A copy of the Medwatch 3500A fo rm 
should be sent to the University of  Michigan Multi-site Coordin ator via fax 
at 734 232 0744 or via email to bdwright@med.umich.edu , 
kemarsh@med.umich.edu  or cto-multisite@med.umich.edu . 
8.5.3 All serious adverse events will be  reported to the IRB per curr ent 
institutional standards.  
8.5.4 The University of Michigan acti ng as the Coordinating Center wi ll be 
responsible for reporting to P fizer by facsimile any Serious Ad verse Event 
that occur during the SAE repor ting period.  The coordinating c enter will 
report the SAE within 24 hours of f irst awareness of the event (immediately 
if the event is fatal  or life-threatening). 
8.5.5 Contact information for Principa l Investigator for SAE Reportin g: 
Maha Hussain, M.D.  
Division of Hematology Oncology Northwestern Medicine 676 N. St. Clair, Suite 850 Chicago, Illinois 60611 Phone: 312-695-6180 Fax: 312-695-4530 
e-mail: maha.hussain@northwestern.edu 
  
8.5.6 The Coordinating Center will disseminate information regarding serious 
adverse events to the participating sites within 5 days of revi ew of the 
information by the Principal Investigator (or her designee in t he event of 
extended absence) only in the case that the event(s) is believe d to be related 
(i.e., possibly, probably, or definite ly) to the study medicati on.  
 
The Coordinating Center, or designee will be responsible for re porting of 
events to the FDA and supporters , as appropriate (outlined in S ection 8.6)  
  
  
54 
 8.6 SERIOUS ADVERSE EVENT REPORTING TO THE FDA  
 
It is the responsibil ity of the IND Sponsor  to submit an IND fo r clinical trials conducted 
with investigational agents and t o ensure that FDA and all part icipating inves tigators are 
promptly informed of significant  new AEs or risks with respect to the investigational 
agent. 
 In this trial, serious unexpected  adverse events believed to be  definitely, probably or 
possibly related to the study treatment will be reported to the  Food and Drug 
Administration via the MedWatch  3500A.  The Coordinating Center, will 
coordinate with the IND Sponsor and/or designee for the reporti ng of any and all 
IND safety reports to the FDA as per the requirements outlined in 21 CFR 312.32. 
 
 9. TISSUE PROCESSING/CORRELATIVE/SPECIAL STUDIES  
 9.1 Tissue / Laboratory Correlative Studies  
 
9.1.1. Collection and Handling of Specimens 
 From each patient, tissue speci mens will be collected from: 
 a) A metastatic site of disease (via biopsy) or adequate metas tatic tissue from prior 
biopsy or resection.  b) Archived prostatectomy or biopsy specimen from the primary prostate tumor (if 
available, via retrieval of prev iously archived specimens). 
 
c) Blood/circulating tumor cells (pre-treatment, week 12,  after 28 weeks of therapy, 
and at progression/or coming off protocol treatment).  
 The rationale, and a brief overvie w, for collection and handlin g of these specimens is 
as described below. Further technical details regarding biopsies of metastatic sites and handling of these biopsy specimens can be found in Appendices B  and C, respectively.   
 
9.1.1a Biopsy of metastatic site: Ra tionale and Procedure (Appendices B and C) 
 
a. Preclinical and clinical data indicates that palbociclib primarily exerts its effect via 
inhibition of intact RB protein phosphorylation. Therefore, onl y patients with intact 
RB expression (as assessed by immunohistochemistry) will be ran domized to 
palbociclib or control arms.  T hus all patients enrolled in thi s trial will either 
undergo a biopsy of a metastatic s ite or have previously underwent a biopsy of 
metastatic disease with evaluable tissue to determine RB status  p r i o r  t o  
randomization. 
 
  
55 
 b. Biopsies must be scheduled for Monday to Thursday to allow for overnight 
shipping to be received by Friday. 
 
c. Patients will be scheduled for a CT-guided biopsy of a bone or  soft tissue abnormality 
consistent with prostate cancer metastasis. The site of biopsy will be determined by 
the radiologist after review of available radiographs, CT, MRI,  and/or bone scan, 
and will be selected based on whatever site is expected to resu lt in the best access 
and best yield.   
 
 An ultrasound (US) can be used for lymph node or soft tissue bi opsies 
provided that the target lym ph node or soft tissue mass is visi ble with the US 
and can be properly accessed.  
 Verbal and written informed consent will be obtained after disc ussion of 
risks (bleeding, infection, soft  tissue and bone injury, inconc lusive biopsy 
results) of the procedure.   
 
 Standard laboratory tests to assess coagulation and bleeding wi ll also be 
completed prior to the procedure. A standard operating procedure for bone 
biopsy is provided in Appendix B .  A standard operating procedure for 
soft tissue biopsy is provided in Appendix C . 
 
 In order to ensure adequate tumor sample as long as it is deeme d safe and 
based on accessibility, target lesion size, specimen integrity, s p e c i m e n  
appearance, intra-procedural bleeding, tumor biopsy should attempt to obtain: 
 
1. Bone biopsy: 2-8 bone biopsy samples .   In addition, at the time of 
biopsy, it will be determined if  a bone marrow aspirate is feasible, and 
if performed, the bone marrow aspi rate will be sent to Universi ty of 
Michigan for analysis.  
2. Lymph node or soft tissue: If obtaining a 1-cm-long 18-gauge core 
specimen, attempts should be made to obtain at least 6 cores.  If 
obtaining a 2-cm-long 18-gauge c ore specimen, attempts should b e 
made to obtain at least 4 cores.   
 
If core biopsy is unsuccessful, a lymph node aspirate  can be obtained, 
but is likely to be insufficient to  allow Rb status determination and 
randomization. 
 d.  The biopsy specimens and the aspirate will be collected and w ill be immediately 
frozen in dry-ice ethanol bath  in Tissue-Tek O.C.T Compound (Sa kura Finetek, 
Torrance, CA) to ensure the integ rity of tissue and proteins fo r both immunoblotting 
and immunohistological analysis of samples. Upon enrollment of each patient on study, sample 
kits containing necessary reagents for tissue collection  (Tissue-Tek standard-
size cryomolds, Tissue-Tek OCT, b lue pads, markers, and an insulated bucket) will be 
shipped to the enrolling site coordinator.   
56 
  
 It is expected that dry ice a nd isopentane will be provided by the enrolling site.   
 
In addition, written SOPs, with specific details regarding tiss ue collection with this kit, 
along with a contact sheet with mailing addresses for sample sh ipment, will be mailed 
to each site coordinator. e.  Each Tissue-Tek cryomold will be labeled with the clinical pr otocol number, the 
patient’s study registration number,  the tissue type and the biopsy time and date.  In addition, a separate information sheet accompanying each specim en will be filled out. 
This information sheet will include various details necessary f or quality assurance of 
the specimen, including:  
1) Date of collection 2) Specimen ID 3) Site from which biopsy obtained (bone versus soft tissue, an d then location) 
4) Type of biopsy device 5) Biopsy diameter: gauge, and length: cm 6) Time biopsy needle introduced 7) Time biopsy snap-frozen on dry ice 8) Time aspirate performed (if applicable) 9) Time aspirate snap-frozen on dry ice 
 
A standard operating procedure for handling of the biopsy and a spirate 
specimens has been attached to t his protocol as Appendix B. 
 Following biopsy, samples from metastatic sites need to be immediately frozen prior to shipment within 24 hours to t he University of Michigan, per shipping directions 
described in 9.1.2.  
9.1.1b Archived Prostate Cancer Samples: Rationale and Procurem ent Procedure 
 
Occasionally, newly metastatic prostate cancer is identified by  biopsy at the time of 
diagnosis or resection.  This tissue may be utilized for RB sta tus assessment, trial 
enrollment and randomization if it is of adequate quality for IHC analysis of RB status. Additionally, previous diagnostic tissue is being requested fro m all patients to assess 
whether RB status and other correlative markers are maintained between diagnostic 
and metastatic samples with or without previous hormonal therap y.   
 If resection specimens are availab le (preferred): The block wit h the highest volume of 
representative tumor histology from the index focus OR 16 unsta ined, unbaked sections 
(4-5 microns in thickness) on g lass slides (charged or uncharge d) should be shipped at 
room temperature to the University of Michigan.  If biopsy specimens are available: Three blocks with the highes t volume of 
representative tumor histology OR 15 unstained, unbaked section s (4-5 microns in 
thickness) on glass slides (charged or uncharged) from up to th ree blocks should be 
shipped at room temperature to t he University of Michigan. If u nstained sections are 
sent, they should be labeled with the block number/letter. If l ess than three blocks have 
57 
 cancer, then all blocks with cancer OR as many unstained sectio ns as can be cut from 
blocks with cancer without exhaustion should be sent.   
 
 9.1.1c: Circulating Tumor Cells: Rationale and Sample Collection Procedure  
 
Blood will be collected pre-treatment, week 12, after 28 weeks of therapy, and at 
progression/or coming off protocol treatment.  Blood samples wi ll be drawn into 10-mL 
evacuated blood draw tube (Cell-Fr ee DNA; Streck) (one at each time point). These 
blood samples can be maintained at room temperature, but must be shipped to Epic 
Sciences within 48 hours after collection , per shipping directions described in 9.1.2.  
 
 9.1.1d: Circulating Tumor DNA: Rationale and Sample Collection Procedure  
 
Blood will be collected pre-treatment, week 12, after 28 weeks of therapy, and at 
progression/or coming off protoc ol treatment. Blood samples wil l be drawn into 10-mL 
evacuated blood draw tubes (Cell-Free DNA; Streck) (one at each time point). These blood 
samples can be maintained at room temperature, but must be shipped to University of 
Michigan within 48 hours after collection , per shipping directions described in 9.1.2.  
 
9.1.2 Shipping of Specimens after Collection 
 
All samples, except the blood samples for CTC analysis,  must be shipped to the 
University of Michigan,  at the following address: 
 
Javed Siddiqui, MS, MT(ASCP, CLsp (MB)) Technical Director Michigan Center for Translational Pathology Room 1138  2900 Huron Parkway Suite 100 Ann Arbor, MI 48105 Phone: (734) 232-0829 Fax: (734) 232-0805 siddiqui@med.umich.edu 
 
Shipping must occur only Monday-Thursday, and an e-mail or phon e call to the 
contact listed on the laboratory contact sheet, alerting them to the shipment, is 
required.  
 9.1.2a Biopsies and aspirates from metastatic sites : If biopsies are performed on 
metastatic sites on Monday thr ough Thursday, the biopsy and asp irate samples should 
be shipped overnight, on dry ice, t o the University of Michigan .  
 9.1.2b Archived Primary Prostate Cancer Tissue : The tumor samples can be 
shipped via standard mail, at room  temperature, to the University of Michigan.  It is 
requested that efforts be made to ship the primary tumor sample s within a month of 
patient enrollment onto the trial.  
58 
 9.1.2c Blood samples NOT for CTC analysis : Blood samples should be obtained on 
Monday through Thursdays, and can be shipped overnight, at room  temperature, to 
the University of Michigan.   
 
9.1.2d Blood samples for CTC analysis : The blood samples should be shipped 
overnight, at room temperature, t o Epic Sciences, at the follow ing address: 
 Epic Sciences  
9381 Judicial Drive, STE 200 
San Diego, CA 92121  
858-356-6610  
 
Shipping must occur only Monday-Thursday, and an e-mail should be sent to 
partners@epicsciences.com, alerti ng to the shipment, the inclus ion of the sample 
ID, number of samples, tracking number, and time of blood draw,  is required.  
Please note that the Epic Scie nces shipping address is to be us ed ONLY FOR 
THE CTC SAMPLES, and that the rem ainder of the samples (metasta ses, 
archived primary tumor, other blood samples) should be sent to the University 
of Michigan address listed above section 9.1.2. 
 
For further details regarding shipping, please refer to Appendi x D, E & F which 
are  the standard operating proce dures for the shipment of samp les.   
 
9.1.3 Sites Performing Correlative Studies   
 
Aside from the circulating tumor cell studies, all correlative studies will be performed at 
the University of Michigan, within the Michigan Center for Tran slational Pathology 
(MCTP). Dr. Felix Feng, translational co-investigator, and Dr. Scott Tomlins, study 
pathologist, will oversee these correlative studies, with additional consultation provided Dr. Karen Knudsen, translational co-investigator. The circulati ng tumor cell studies will 
be performed by Epic Sciences. 
 
9.1.4 Processing of Specimens aft er Receipt at the University o f Michigan  
 
a. With the receipt of each biopsy specimen, Javed Siddiqui at the  University of 
Michigan (or a pre-specified desi gnee) will place the samples i n the -80˚C tissue 
repository described below and will record two additional items  for further quality 
assurance: 
 1) The date/time of receipt of the biopsy specimen at the Univ ersity of Michigan 
 2) The date/time that the biopsy specimen is placed at -80°C 
 b. Biopsies from metastatic sites: The frozen tissue samples from  either biopsy or from 
preexisting metastatic tissue, obtained for research from patie nts taking part in this 
protocol will be held in the University of Michigan Prostate On cology Program Tissue 
Bank.  The Tissue Bank is located in Room 1143, 2900 Huron Park way, Suite 100, 
University of Michigan, Ann Arbor, Michigan 48105. This laboratory has multiple -80˚C freezers, one of which will be devoted to the biopsies fro m this trial. The freezers 
59 
 have an alarm system and self-dialing emergency system. It is a nticipated that at least 
two samples will be obtained from each metastatic biopsy.   
 From bone biopsies, these metastases may consist of two biopsie s or a biopsy and an 
aspirate. One sample from each metastatic biopsy (the biopsy sa mple in cases where 
there is a biopsy sample and an aspirate) will be fixed in form alin shortly after receipt 
at the University of Michigan.  Eight 5 um section slides will be cut from this formalin 
fixed sample -- one for H&E staining to confirm the presence of  tumor, two for 
determination of RB status and th e others for correlative studi es.  The remaining 
formalin-fixed metastatic biopsy sample will be utilized for ta rgeted 
transcriptome/genome sequencing.  Where feasible, transcriptome sequencing and whole exome capture will be performed on remaining frozen metas tatic biopsy 
materials.  
c. Primary tumor samples: Retrieved primary tumor samples will be stored at room 
temperature in the University of  Michigan Prostate Oncology Pro gram Tissue 
Bank, and will be assessed for RB pathway biomarkers, as well a s for genetic 
alterations by focused targeted tr anscriptome/genome sequencing .  
 
d. Blood samples for circulating tumor DNA studies: Blood samples received will 
have genomic DNA extracted per st andard protocols.  Samples will then be stored 
in -80C freezer.  Further analyse s of these blood samples will proceed once the 
genomic studies have been performed on the biopsy samples.24-28 
 
e. Blood samples for circulating tumor cell studies:  The Epic Sci ences platform will be 
utilized for circulating tumor cell analyses.24-28 Peripheral blood samples will be drawn 
at accruing sites following informed consent and processed foll owing standard 
operating procedures. Using a standardized and ISO-certified sh ipping process, 
samples are transferred to the Epic Sciences central laboratory . Samples are then 
processed after 48 hours of blood draw. The red blood cells are  lysed and the remaining 
nucleated cells are plated on custom glass slides and frozen fo r storage. As needed, 
blood sample slides are thawed and processed to bind the approp riate cell markers with 
fluorescently labeled antibodies. Depending on peripheral blood  counts, up to 16 slides 
are generated from each subject. Two to four processed slides, representing one patient 
test, the identification of CTCs consists of three markers (DAP I-nucleus, cytokeratin – 
epithelial marker, and CD-45 – white blood cell marker) and are  imaged on custom-
built automated slide imagers. The resulting images are then au tomatically processed 
to produce data for technical analysis which consists of removi ng imaging artifacts and 
selecting potential CTC candidates which are then presented in a web-based report to a pathologist for final review. Remaining slides are stored for  subsequent analysis.  
These subsequent analyses will include immunofluorescence for t he androgen receptor 
(AR), including AR C-terminal and AR N-terminal expression.  
9.2   Description of RB Assessment and Correlative Studies  
 
9.2.1 RB Status Determination  
A s  p a r t  o f  t h e  p a t i e n t  s e l e c t i o n  for this trial, patients will undergo 
immunohistochemistry (IHC) for tot al RB status in a CLIA certif ied laboratory, per a 
previously published RB IHC protocol.32 IHC will be performed for RB using a mouse-
60 
 anti-RB monoclonal antibody (BD Biosciences, San Jose, CA, G3-2 45) using 
automated IHC staining on the Ventana Medical Systems Benchmark  Ultra autostainer. 
Slides are pre-treated with CC1 for 40 minutes, incubated with primary antibody for 16 
minutes at 37 C (1:1600 dilution in Ventana diluent 90040). Tum or RB status will be 
determined by assessing staining in at least 100 tumor cells (o r all cells if less than 100 
cells are present). Nuclear RB staining intensity in tumor cells will be assessed as 
negative (0), weak (1+), moderate (2+) or strong (3+). Inflamma tory, endothelial and/or 
stromal cells will be used as internal positive controls. Based  on validation studies 
using samples with known RB retention or deletion, tumor sample s with >5% of cells 
showing at least moderate RB expression or 20% of tumor cells s howing at least weak 
RB expression will be considered positive and eligible for the trial. For correlative studies, RB staining will be quantified in positive patients by  multiplying the 
percentage of positive tumor cells by the average intensity of positive tumor cells 
(1=weak, 2=moderate , 3=strong).     
 
9.2.2 Identification of Biomarkers Predictive of Responsiveness  to Palbociclib 
The RB pathway can be disrupted in human cancers via multiple m echanisms,5 and 
because alterations in the RB pathway could modulate the respon se to palbociclib, 
correlative studies will assess for potential biomarkers along the RB pathway via 
multiplexed IHC.  Because the RB protein can be inactivated by posttranslational 
modifications that are the subject of oncogenic (e.g., cyclin D 1 
overexpression/amplification) or tumor suppressive (e.g., p16in k4a silencing) 
alterations, IHC for cyclin D1, cyclin D1B (a variant associate d with aggressive 
disease), and p16 will be performed.33 Additionally, as RB also plays a critical role in 
the response to many antiprolifera tive stresses that are engage d by therapeutic agents,5 
immunohistochemistry will also be performed for Ki-67, a common marker of cell 
proliferation.  As previous studies from our group have defined  a signature of RB loss,7 
immunohistochemistry will be performed for key RB target genes (such as Cyclin A 
and MCM7).  Finally, we will also assay the status of the RB interactor, E2F1, via IHC. 
In both the primary tumor samples and metastatic biopsies, IHC biomarkers will be 
quantified by multiplying the percentage of positive tumor cell s by the average 
intensity of positive tumor cells (0=negative to 3=strong) by e xperienced pathologists. 
For Ki-67, proliferative index will be determined by quantifyin g the percentage of 
tumor cells with nuclear staini ng. Statistical analyses plans f or these correlative studies 
are described in Section 13.   9.2.3 Targeted DNA sequencing and expression profiling.  While the ultimate goal 
would be to perform comprehensive sequencing (see below) on all  the biopsy studies 
from this clinical trial, the tissue limitations regarding tumo r quantity may preclude 
comprehensive sequencing on a subset of samples.  Specifically,  in patients in which 
only one biopsy core can be obtained, this single core will be converted to a formalin-
fixed paraffin embedded (FFPE) specimen, to allow assessment of  t h e  p r i m a r y  
biomarker (RB) using a validated assay (IHC) in a CLIA-certifie d laboratory.  While 
comprehensive sequencing cannot be reliably performed on FFPE b iopsy specimens, 
targeted sequencing and expression profiling can be performed o n these limited FFPE 
tissues. Specifically, we will assess a novel panel of recurren t alterations identified 
61 
 across prostate cancer profiling studies.  
 DNA and RNA will be co-isolated using a commercially available kit (Qiagen All Prep DNA/RNA FFPE) according to the manufacturer’s instructions. For  DNA based 
alterations, a Haloplex custom capture panel (Agilent Technolog ies) will be utilized 
with Ion Torrent-based sequencing on the PGM/Proton sequencing systems according 
to the manufacturer’s instructions. Our team (S Tomlins) has pr eviously developed a 
Haloplex Custom Design (Agilent ) for capture-based targeted sequencing of complete 
coding sequences of 80 genes prev iously reported as significantly mutated in prostate 
cancer, 46 therapeutic targets, and 50 causal cancer genes; thi s approach has been 
optimized for 200 ng of genomic DNA.  We will adapt this platfo rm to include potential 
biomarkers of response as identified in Section 9.2.1.  Identif ied variants will be 
assessed for potential as drivers of resistance to CDK4/6 inhib ition or ADT based on 
known roles in oncogenesis and prostate cancer, comparison to O ncomine and 
COSMIC mutational data, and comparison to CRPC tissue expressio n profiles (as 
previously published by our group and others
16,34), and integration with AR chip-seq 
profiles.35  
 qPCR for targeted gene expression profiling will be performed u sing a previously 
validated panel of 48 prostate cancer related genes, supplement ed with potential 
biomarkers of response as identified in Section 9.2.1. Reverse transcription will be 
performed on 300ng of isolated RNA from each tissue sample usin g gene specific 
priming with subsequent qPCR using FFPE optimized TaqMan assays . Genes have 
been selected to assess AR signaling status (including both AR induced/repressed and 
neuroendocrine genes), known prostate cancer fusions (through 5 ’ and 3’ assays for 
ETS genes, FGFR2, RAF/RAS family members, etc), potential thera peutic targets in 
other malignancies (such as 5’ and 3’ assays for ALK and RET over-expression), as well as housekeeping genes. qPCR will be performed on the ABI Quantstudio 12K flex system using TaqMan Universal PCR Mastermix and 384 well TLDA c ards. 
 
9.2.4 Comprehensive next-generation sequencing.  For specimens in which enough 
tumor tissue was present (i.e., additional frozen biopsy specim ens), exome sequencing 
and RNA-sequencing using Illumina based technology will be perf ormed as described 
using robust protocols and pipelines previously optimized by our team.16,35-39 Standard 
pipelines will be employed as described to quantify gene expression, and identify gene 
fusions, point mutations, indels  and copy number variants.   
62 
 9.2.5 Circulating tumor DNAs as predictive biomarkers of respon se to androgen 
deprivation therapy alone or in combination with Palbociclib.  
 
Detection of DNA in the serum o f patients with metastatic prostate cancer, may allow 
determination of tractable bioma rkers of disease status and res ponsiveness to therapies.  
Here we will collected and analyze serum for circulating tumor DNA to determine if 
we can identify markers of disease state and responsiveness.40  In particular, potential 
biomarkers identified via target ed sequencing and expression pr ofiling of the metastatic 
biopsy samples (see 9.2.3) will be assessed within the blood sa mples as well, to 
determine if these blood samples can serve as a less invasive a pproach of querying 
relevant biomarkers.   
9.2.6 Circulating Tumor Cell (CTC) Count and Heterogeneity as p redictive 
biomarkers of response to androgen deprivation therapy alone or  in combination 
with Palbociclib.   CTCs will be enumerated using the Epic Sciences System utiliz ing 
automated fluorescence- based microscopy systems that permit co mputer-generated 
reconstruction of cellular images. In addition, immunofluoresen ce-based approaches 
assessing for CK, CD45, DAPI, and AR expression will be used to  determine the extent 
of CTC heterogeneity (distributi on of CTC phenotypes, such as n ucleoli CTCs, CTC 
clusters, CK- CTCs, CK speckled CTCs, small CTCs, AR nuclear CT Cs, and AR 
cytoplasmic CTCs).  Associations between outcome and CTC count/ heterogeneity will 
be performed as per Section 13.4.  
  
63 
 10. STUDY CALENDAR  
  Cycle 1 Cycle 2-7 Subsequent Cycles  
Off 
Treatme
nt g Required 
Treatment or Studies Pre- 
Study Day 
1 Day 
8 Day 
15 Day 
21 Day 
28 Day 
1 Day 
8 Day 
15 Day 
21 Day 
28 ARM 1 ADT 
Alone ARM 2 
palbociclib + 
ADT
h 
Bicalutamide  X------------------------------------------------ ---------------------------------X Daily Daily  
LHRH Therapy  X------------------------------------------------ ---------------------------------X Continuous Continuous  
PD-0332991 (Arm 2) 3 weeks on /1 week off
h  X-------------------------X  X-------------------------X  NA D ays 1-21  
Informed consent X              
History & Physical X X     X     Every 12 
weeks Every 12 
weeks X 
Weight & PS X X     X     Every 12 
weeks Every 12 
weeks X 
H e i g h t  X               
Concurrent meds X X     X     Every 12 
weeks Every 12 
weeks  
Metastatic disease 
biopsy X               
Serum PSAa X X     X     Every 4 weeks Every 4 weeks X 
CBC w/diff, pltsb X  X  X  X    X   Xb   Every 12 
weeks Every 4 weeks X 
Serum chemistryc X  X  X  X    X      Every 12 
weeks Every 4 weeks X 
PT/PTT/INR X               
Correlative Blood 
Samples for 
circulating tumor 
DNA and CTC analysis
d  X      Xd     Xd Xd Xd 
EKG e X       Xe        
Archived Tissues  X               
Adverse event evaluation  X------------------------------------------------------------- ---------------------X X X X 
Tumor measurement X 
Measured  after 28 weeks  +/- 1 week Measure every 24 weeks(+/- 1 
week) for 2 years then annually 
unless clinically indicated X 
Radiologic evaluation 
f X X 
a:  For patients who are initiated on ADT prior to registration , pre androgen deprivation PSA should be recorded. 
b:  Arm 2 may consider adding addi tional interim CBCPD during a dditional cycles if clinically i ndicated.  Arm 1 patients do no t need repeat CBC during any cycle unless 
medically indicated. c:  Albumin, alkaline phosphatase , total bilirubin, bicarbonate , BUN, calcium, chlori de, creatinine, gluco se, phosphorus, pota ssium, total protein, SGOT [AST], SGPT 
[ALT], sodium, magnesium.  Arm 1 patients do not need repeat Ch emistry during cycle 1 unless medically indicated. 
d: Pretreatment, week 12, after  28 weeks of therapy, and at pro gression/or coming off protocol treatment. 
e: EKG should be done on day 1 of cycle 2 for arm 2 patients.  If there is no abnormality, then no additional EKG’s are needed .  If abnormal, then  monthly EKG for 7 
cycles can be performed.  Arm 1 patients do not need repeat EKG unless clinically indicated 
f.  Include bone scan , CT/MRI abdomen and pelvis, CT/MRI chest or CXR as appropriate.   All dise ase sites must be reassessed. 
g:  Follow-up for patients taken off treatment for reasons othe r than progression will be done ev ery 12 weeks. These visits wi ll include H&P and labs as outlined in 
subsequent cycle arm 1 column.   Imaging will be done q 24 weeks .  Clinical, Lab and imaging will be done for 2 years or until progression whichev er comes first. 
64 
 A cycle is 28 days. For both arms scans to assess disease will be performed after 28 weeks calculated from “Day 1” 
of protocol.  Return visits aft er initiation of therapy can be done within ± 4 days from actual due date.  Lab draws for 
Arm 2 (CBC w/diff, plts and Serum chemistry) on Cycle 1 (days 8  and 15), and Cycles 2-7 (D15) can be done ± one 
day.  
  h:  For patients coming every 12 weeks appropriate supply of pa lbociclib can be provided per institutional guidelines and care ful instructions regarding the dosing.  
 
65 
 11. MEASUREMENT OF EFFECT  
 
 For the purposes of this study, patients wi ll have a PSA evalua tion at the start of each new 
cycle with primary endpoint assessment after 28 weeks of therap y.  Radiologic response 
will be determined after 28 weeks plus or minus 1 week (or as p rompted by symptoms) 
and every 24 weeks plus or minus 1 week thereafter while on study for 2 years, then 
annually and otherwise if  clinically indicated. 
 
 Response and progression will be evaluated in this study using the new international 
criteria proposed by the revise d Response Evaluation Criteria i n Solid Tumors (RECIST) 
guideline (version 1.1).41  Changes in the largest diameter (unidimensional measurement) 
of the tumor lesions and the shor test diameter in the case of m alignant lymph nodes are 
used in the RECIST criteria. 
 
11.1 Definitions 
 
Evaluable for toxicity.  All patients will be evaluable for toxicity from the time of 
their first treatment with ADT with or without palbociclib.  Evaluable for primary endpoint.  All patients randomized to eit her Arm 1 or Arm 2 
and receive at least one cycle of therapy or are removed from treatment due to toxicity are evaluable. Patients who are randomized but do not complete 1 cycle of 
treatment due to reasons other than toxicity will be replaced. 
 
Evaluable for objective response.  Only those patients who have measurable disease 
present at baseline and have had their disease re-evaluated wil l be considered 
evaluable for response.  These patients will have their response classified according to the definitions stated below.    Evaluable non-target disease resp onse.  Patients who have lesio ns present at 
baseline that are evaluable but do not meet the definitions of measurable disease 
and have had their disease re-ev aluated will be considered eval uable for non-target 
disease.  The response assessment is based on the presence, abs ence, or unequivocal 
progression of the lesions.   Measurable disease.  Measurable lesions are defined as those th at can be accurately 
measured in at least one dimension (longest diameter to be reco rded) as >20 mm 
by chest x-ray, as >10 mm with CT scan, or >10 mm with CT scan,  MRI, or calipers 
by clinical exam.  All tumor measurements must be recorded in m illimeters (or 
decimal fractions of centimeters). 
 
Note:  Tumor lesions that are situated in a previously irradiat ed area might or might 
not be considered measurable.  Decision should be made in consu ltation with 
primary investigator.  Malignant lymph nodes.  To be cons idered patholo gically enlarge d and measurable, 
a lymph node must be >15 mm in s hort axis when assessed by CT s can (CT 
66 
 scan slice thickness recommended to be no greater than 5 mm).  At baseline and in 
follow-up, only the short axis will be measured and followed. 
 
Non-measurable disease.  All othe r lesions (or sites of disease ), including small 
lesions (longest diameter <10 mm or pathological lymph nodes wi th ≥10 to <15 
mm short axis), are considered non-measurable disease.  Bone le sions, 
leptomeningeal disease, ascites,  pleural/pericardial effusions,  lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal ma sses (not followed 
by CT or MRI), are considered as non-measurable. 
 Note:  Cystic lesions that meet the criteria for radiographical ly defined simple cysts 
should not be considered as malignant lesions (neither measurab le nor non-
measurable) since they are , by definition, simple cysts. 
 ‘Cystic lesions’ thought to repre sent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurabilit y described above. 
However, if non-cystic lesions are present in the same patient,  these are preferred 
for selection as target lesions. 
 
Target lesions.  All measurable lesions up to a maximum of 2 le sions per organ and 
5 lesions in total, representa tive of all involved organs, shou ld be identified as 
target lesions and recorded and measured at baseline.  Target lesions should be 
selected on the basis of their size (lesions with the longest d iameter), be 
representative of all involved organs, but in addition should b e those that lend 
themselves to reproducible repeated measurements.  It may be th e case that, on 
occasion, the largest lesion does not lend itself to reproducib le measurement in 
which circumstance the next largest lesion which can be measure d reproducibly 
should be selected.  A sum of the diameters (longest for non-no dal lesions, short 
axis for nodal lesions) for all target lesions will be calculat ed and reported as the 
baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline sum diamete rs will be used as 
reference to further characterize any objective tumor regression in the measurable dimension of the disease.  Non-target lesions.  All other lesions (or sites of disease) in cluding any measurable 
lesions over and above the 5 target lesions should be identifie d as non-target 
lesions and should also be recorded at baseline.  Measurements of these  lesions are 
not required, but the presence, absence, or in rare cases unequ ivocal progression of 
each should be noted throughout follow-up.  
 
11.2     Response and Progression Criteria  
 
11.2.1  Outcomes based on post-therapy PSA changes  
 
o Primary Endpoint will be stable or declining PSA < 4ng/mL after  28 weeks of 
therapy  
 
67 
 o Secondary Endpoint will be rate of undetectable PSA  after 28 weeks of therapy 
(<0.2ng/mL) 
 
o These definitions are intended to  characterize the PSA changes on study for the 
purpose of reporting of results.    
 
Complete Response (CR):  Undetectable PSA (<0.2 ng/ml) that is confirmed by 
another PSA level at no less than 4 weeks interval. 
 
Partial Response (PR):  PSA level between 0.2ng/ml and 4ng/ml.. 
 
Stabilization (SD):  Patients who do not meet the criteria for PR or PD for at leas t 
90 days on study (2 cycles of treat ment) will be considered sta ble 
 
Progression (PD):  25% increase ove r baseline or nadir whichever is lower and an 
increase in the absolute value of PSA level by 2 ng/ml that is confirmed by another 
PSA level at no less than 4 weeks interval. 
  
11.2.2  Outcomes based on evaluation of target lesions 
     Complete Response (CR):  Disappearance of all target  lesions.  Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to <10 
mm. 
 
    Partial Response (PR):  At least a 30% decrease in the sum of the diameters of 
target lesions, taking as reference the baseline sum diameters.  
 
    Progressive Disease (PD): At least a 20% increase in the sum of the diameters 
of target lesions, taking as reference the smallest sum on stud y (this includes the 
baseline sum if that is the smallest on study).  In addition to  the relative increase of 
20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note: the appearance of one or more new lesions is also considered pr ogressions). 
 
    Stable Disease (SD):  Neither sufficient shrinkage to  qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest su m diameters while on 
study. 
 
11.2.3  Evaluation of Non-Target Lesions 
     Complete Response (CR):  Disappearance of all non-target lesions and 
normalization of tumor marker level.  All lymph nodes must be n on-pathological 
in size (<10 mm short axis). 
   
Non-CR/Non-PD: Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits. 
 
Progressive Disease (PD):  Appearance of one or more new lesions and/or 
68 
 unequivocal progression  of existing non-target lesions.  Unequivocal progression  
should not normally trump target lesion status.  It must be rep resentative of overall 
disease status change, not a single lesi on increase.     
Although a clear progression of “ non-target” lesions only is ex ceptional, the 
opinion of the treating physician should prevail in such circum stances, and the 
progression status should be confirmed at a later time by the r eview panel (or 
Principal Investigator). 
 
11.2.4  Outcomes based on Radionuclide bone scans  
 
The subjectivity in interpreting s erial changes in a radionucli de bone scan is well 
recognized.  Thus, the primary outcome will be whether the scan  is stable or 
improved, vs. worse or progression.  Changes in intensity will not be used as an 
outcome measure. 
 
Stable or Improved : A stable or improved classif ication requires that no new 
lesions appear or that new pai n has not developed in an area th at was previously 
visualized. 
 
Progression (Non-Response) : Appearance of two or more  new skeletal lesions. 
An increase in the size or intensity of known skeletal lesions will not be 
considered progression . 
 
    
11.3 Methods for Evaluation of Measurable Disease 
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  
All baseline evaluations should be  performed as closely as poss ible to the beginning of 
treatment and never more than 6 w eeks before registration.  
 The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up . Imaging-based evaluation is 
preferred to evaluation by clinical examination unless the lesi on(s) being followed cannot be 
imaged but are assessable by clinical exam. 
 Clinical lesions:  Clinical lesions will only be con sidered measurable when they a re 
superficial ( e.g., skin nodules and pal pable lymph nodes) and 10 mm diameter as 
assessed using calipers ( e.g., skin nodules).  In the case of skin lesions, 
documentation by color photography, including a ruler to estima te the size of the 
lesion, is recommended.  
 
Chest x-ray:   Lesions on chest x-ray are acceptable as measurable lesions when they 
are clearly defined and surr ounded by aerated lung.  However, C T is preferable.  
 
Conventional CT and MRI:  This guideline has defined measurabil ity of lesions on 
CT scan based on the assumption that CT slice thickness is 5 mm  or less.  If CT 
69 
 scans have slice thickness greater than 5 mm, the minimum size for a measurable 
lesion should be twice the slice thickness.  MRI is also accept able in certain 
situations (e.g.  for body scans).   
 
U se o f  MR I rem ain s a co m p lex  issu e.   MR I h as ex ce llen t  co n tra st , spatial, and 
temporal resolution; however, there are many image acquisition variables involved 
in MRI, which greatly impact image quality, lesion conspicuity,  and measurement.  
Furthermore, the availability o f MRI is variable globally.  As with CT, if an MRI 
is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with 
CT, the modality used at follow- up should be the same as was us ed at baseline and 
the lesions should be measured/assessed on the same pulse seque nce.  It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pu lse sequence 
parameters for all scanners, body parts, and diseases.  Ideally , the same type of 
scanner should be used and the image acquisition protocol shoul d be followed as 
closely as possible to prior scans.  Body scans should be perfo rmed with breath-
hold scanning techniqu es, if possible. 
   Bone disease:  Bone disease wi ll be evaluated using Radionucl ide bone scan. 
 
11.4 Progression-Free Survival: 
 
Progression-free survival (PFS) i s defined as the duration of t ime from start of treatment 
to time of progression or deat h, whichever occurs first.  
 
11.5 Evaluation of Best Overall Response 
  
The best overall response is the b est response recorded from th e start of the treatment 
until disease progression/recurrence (taking as reference for progressive disease the 
smallest measurements recorded since the treatment started).  The patient's best response assignment will depend on the ach ievement of both measurement a nd confirmation 
criteria.  
 
 For Patients with Measurable Disease ( i.e., Target Disease) 
 
Target 
Lesions Non-Target Lesions New Lesions Overall Response Best Overall Response when Confirmation is Required* 
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non-PD No PR 
>4 wks. Confirmation** CR Not 
evaluated No PR 
PR Non-
CR/Non-PD/not evaluated No PR 
70 
 SD Non-
CR/Non-
PD/not evaluated No SD 
Documented at least once >4 wks. from baseline** 
PD Any Yes or 
No PD 
no prior SD, PR or CR Any PD*** Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evid ence of a 
new lesion. 
** Only for non-randomized trials with response as primary endpoint. *** In exceptional circumstances, unequivocal progression in no n-target 
lesions may be accepted as disease progression. 
Note: Patients with a global deterioration of health status req uiring 
discontinuation of treatment wit hout objective evidence of dise ase 
progression at that time should be reported as “ symptomatic 
deterioration.”   Every effort should be made to document the objective 
progression even after dis continuation of treatment . 
 For Patients with Non -Measurable Disease ( i.e., Non Target Disease) 
 
    
 
 
       11.6 Duration of Response 
 
11.6.1 Duration of overall response:  The duration of overall r esponse is measured from the 
time measurement criteria are met for CR or PR (whichever is fi rst recorded) until the first 
date that recurrent or progressi ve disease is objectively docum ented (taking as reference for 
progressive disease the smallest measurements recorded since the treatment started). 
 The duration of overall CR is measured from the time measuremen t criteria are first met for 
CR until the first date that progressive disease is objectively  documented.   
 Non-Target Lesions New Lesions Overall Response 
CR No CR 
Non-CR/non-PD No Non-CR/non-
PD* 
Not all evaluated No not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 
*  ‘Non-CR/non-PD’ is preferred over ‘stable disease’ for non-t arget disease since SD 
is increasingly used as an end point for assessment of efficacy in some trials so 
to assign this category when no lesions can be measured is not advised 
7 1 
 1 1. 6. 2  D urati o n of sta ble disease:  Sta ble disease is meas ure d  fr o m t he start of t he treat me nt 
u ntil  t he  criteria  f or  pr o gressi o n  are met, ta ki n g as refere nce   t he  s mallest  meas ure me nts 
rec or de d si nce t he treat me nt st arte d, i ncl u di n g t he baseli ne me as ure me nts.  
 
1 2.   D A T A M A N A G E M E N T A N D M O NI T O RI N G  
 
1 2. 1   D at a a n d S afet y M o nit ori n g Pr oce d ures 
 
T he Data a n d Safet y M o nit ori n g B oar d ( D S M B) of T he U ni versit y of Mic hi ga n C o m pre he nsi ve 
Ca ncer  Ce nter  ( U M C C C)  is  t he  D S M B  f or  t his  st u d y.    T his  c o m mitt ee  is  res p o nsi ble  f or 
m o nit ori n g t he safet y a n d da ta i nte grit y of t he trial. 
 
Eac h partici pati n g site is re q uire d t o ha ve its o w n Data a n d Sa fet y M o nit ori n g C o m mittee ( D S M C) 
f or t he st u d y.  T his c o m mittee will be c o m p ose d of t he l ocal si te pri nci pal i n vesti gat or, site c o- 
i n vesti gat or(s),  site  data  ma na ger  or  st u d y  c o or di nat or  a n d  ot h er  me m bers  of  t he  st u d y  staff 
i n v ol ve d i n t he c o n d uct of t he tri al.  D uri n g t he c o m mittee’s q uarterl y meeti n g, t he site pri nci pal 
i n vesti gat or will disc uss matters relate d t o: 
 
  E nr oll me nt rate relati ve t o e x pectati o ns, c haracteristics of partici pa nts 
  Safet y of st u d y partici pa nts ( Seri o us A d verse E ve nt & A d verse  E ve nt re p orti n g) 
  A d here nce t o pr ot oc ol  ( pr ot oc ol de viati o ns) 
  C o m plete ness, vali dit y a n d i nte grit y of st u d y data 
  Rete nti o n of st u d y partici pa nts 
 
T hese  meeti n gs  are  t o  be  d oc u me nte d  b y  t he  site  data  ma na ger  or   st u d y  c o or di nat or  usi n g  t he 
Pr ot oc ol  S pecific  Data  a n d  Safe t y  M o nit ori n g  Re p ort  ( D S M R),  si g ne d  b y  t he  site  pri nci pal 
i n vesti gat or or c o-i n vesti gat or.  Eac h site is re q uire d t o s u b m it t he c o m plete d D S M R t o t he M ulti- 
Site C o or di nat or at t he U ni versit y of Mic hi ga n Cli nical Trials Office o n a q uarterl y basis t o get her 
wit h ot her perti ne nt d oc u me nts. 
 
Si milarl y, pr ot oc ol de viati o ns are  t o be d oc u me nte d usi n g t he N otice of Pr ot oc ol De viati o n F or m 
a n d re q uires t he si g nat ures of b ot h t he sites data ma na ger or s t u d y c o or di nat or a n d t he site pri nci pal 
i n vesti gat or or c o-i n vesti gat or. T hese re p orts are t o be se nt t o t he U ni versit y of Mic hi ga n Cli nical 
Trials Office wit hi n 7 cale n dar da ys of a ware ness of t he e ve nt a n d o n a q uarterl y basis wit h t he 
Pr ot oc ol S pecific Data a n d Safet y M o nit ori n g Re p ort. 
 
T he Cli nical Trials Office is res p o nsi ble f or c ollati n g all t he  Data a n d Safet y M o nit ori n g Re p orts 
fr o m all t he partici pati n g sites, a n d pr o vi di n g t he i nf or mati o n  t o t he Data Safet y M o nit ori n g B oar d. 
 
1 2. 2   Cli nic al M o nit ori n g Pr oce d ures 
 
Cli nical  st u dies  c o or di nate d  b y  T he  U ni versit y  of  Mic hi ga n  C o m p r e he nsi ve  Ca ncer  Ce nter 
( U M C C C) m ust be c o n d ucte d i n acc or da nce wit h t he et hical pri nci ples t hat are c o nsiste nt wit h 
G o o d Cli nical Practices ( G C P) a n d i n c o m plia nce wit h ot her a p pl ica ble re g ulat or y re q uire me nts. 
A d verse  e ve nt  lists,  g ui deli nes,  a n d  i nstr ucti o ns  f or  A E  re p ort i n g  ca n  be  f o u n d  i n  Secti o n  8. 0 
( A d verse E ve nts: List a n d Re p orti n g Re q uire me nts). 
 
72 
 This study will be monitored by a representative of the Clinica l Trials Office (CTO) of the 
UMCCC. Monitoring visits will be made during the conduct of the  study and at study close-out. 
 
Prior to subject recruitment, a participating site will undergo  site initiation meeting to be conducted 
by the Clinical Trials Office. This will be done as an actual s ite visit; teleconference, 
videoconference, or web-based mee ting after the site has been g iven access to the study database 
and assembled a study reference binder.  The site’s principal investigator and his study staff should make every effort in attending the site initiation meeting. Stu dy–related questions or issues 
identified during the site initiation meeting will be followed- up by the appropriate UMCCC 
personnel until they have been answered and resolved.  Monitoring of this study will include both ‘Centralized Monitor ing’, the review of source 
documents at the CTO and ‘On-site Monitoring’, an actual site v isit.  The first ‘Centralized’ visit 
should occur after the first subj ect enrolled completes the fir st treatment cycle .  The study site will 
send the de-identified source documents to the CTO for monitori ng.  ‘Centralized’ monitoring may 
be requested by the CTO if an amendment requires changes to the  protocol procedures. The site 
will send in pertinent de-identified source documents, as defined by the CTO for monitoring.   The first annual ‘On-site’ monitoring visit should occur after the first five study participants are 
enrolled or twelve months after a study opens, whichever occurs  first.  The annual visit may be 
conducted as a ‘Centralized’ visit if less than three subjects have enrolled at the study site.  The 
type of visit is at the discretion of the CTO.  At a minimum, a  routine monitoring visit will be done 
at least once a year, or once during the course of the study if  the study duration is less than 12 
months. The purpose of the se visits is to verify: 
 
 Adherence to the protocol 
 Completeness and accuracy of st udy data and samples collected 
 Proper storage, dispensing and inventory of study medication 
 Compliance with regulations 
 During a monitoring visit to a site, access to relevant hospita l and clinical records must be given 
by the site investigator to the CTO representative conducting t he monitoring visit to verify 
consistency of data collected on the CRFs with the original sou rce data.  While most patient cases 
will be selected from patients accrued since the previous monitoring visit, any patient case has the potential for review.  At least one or more unannounced cases w ill be reviewed, if the total accruals 
warrant selection of unannounced cases.   The Clinical Trials Office expects the relevant investigational  staff to be available to facilitate the 
conduct of the visit, that source documents are available at th e time of the visit, and that a suitable 
environment
 will be provided for review of study-related documents. Any iss ues identified during 
these visits will be communicated to the site and are expected to be resolved by the site in a timely 
manner.  For review of study-related documents at the CTO, the site will be required to ship or fax documents to be reviewed.    Participating site will also undergo a site close-out upon comp letion, termination or cancellation 
of a study to ensure fulfillment of study obligations during th e conduct of the st udy, and that the 
site Investigator is aware of his/her ongoing responsibilities. In general, a site close-out is 
73 
 conducted during a site visit; however, site close-out can occu r without a site visit if all of the 
following apply: 
 
 No patient has signed the Inform ed Consent Form and has enrolle d into the study 
 Investigational agent  has not been dispensed 
 All investigational agent and materials have been returned as d e f i n e d  f o r  t h e  s t u d y  o r  
destroyed and accounted for properly.  
12.3  Quality Assurance and Audits 
 
The Data Safety Monitoring Board can request a ‘for cause’ audi t of the trial if the board identifies 
a need for a more rigorous evaluation of study-related issues. A “for cause” audit would be 
conducted by the Quality Assuranc e Review Committee (QARC) of t he University of Michigan 
Comprehensive Cancer Center.  A regulatory authority (e.g., FDA)  may also wish to conduct an inspection of the  study, during its 
conduct or even after its completion. If an inspection has been requested by a regulatory authority, the site investigator must immediately inform the Clinical Tria ls Office that such a request has 
been made. 
 
13. STATISTICAL CONSIDERATIONS  
 
 13.1 Statistical Design 
 
The primary analysis will be assessment of the proportion of pa tients who achieve a 
PSA < 4ng/mL after 28 weeks of treatment in each arm.  For purp oses of the primary 
endpoint, day 1 will be the random ization date for patients wit h pre-registration ADT 
treatment and the treatment start date for patients’ naïve to A DT at registration.  The 
difference in proportions will be reported with the mid p-value  test of the 2X2 table 
with a one-sided type I error o f 10%.   The binomial proportions with the corresponding 
Wilson score 90% binomial confidence intervals will also be rep orted by arm.  
 
The primary endpoint of the st udy is to compare the proportion of patients who have a 
PSA < 4ng/mL after 28 weeks of protocol treatment between patie nts stratified by pre-
registration ADT treatment and extent of disease and randomized to combined androgen deprivation (ADT: LHRH  agonist + bicalutamide) and tho se randomized to 
combined ADT + palbociclib.  ADT alone (Arm 1) is expected to r esult in 70% of 
patients achieving PSA < 4ng/mL after seven months of protocol treatment.  It is 
hypothesized that the ADT + palboc iclib arm (Arm 2) will have a  20% absolute 
increase in proportion to 90% (H A: p2 – p 1 > 0).  The null hypothesis is no difference in 
proportions (H 0: p2 – p 1 ≤ 0).  Patients will be randomi zed using a 1:2 (Arm 1: Arm 2) 
schema stratified by extent of disease. Up to 95 patients may n eed to be registered 
(enrolled) in order to obtain the 60 evaluable patients. All pa tients randomized will be 
evaluable if they receive 1 cycle of treatment or are removed d uring treatment due to 
toxicity.  Patients who are randomized but do not complete 1 cy cle of treatment due to 
reasons other than toxicity will be replaced.  With 20 evaluabl e patients on ADT alone 
and 40 evaluable patients on combination ADT + palbociclib, the re is 64.2% power to 
74 
 detect a 20% difference in pr oportions with a one-sided type I error of 0.10 using the 
mid p-value method of the Fisher’s exact test.  
 
With regard to power of the study, the focus of this trial is f easibility and to detect a 
signal, as described by our aims for this small targeted early phase II trial. The 
compromise of the power was done because of the overwhelming be nefit to include a 
control population since there is  no data on the rate of PSA de clines after 28 weeks of 
ADT in the targeted RB positive population. The plan is to use the mid p-value test as 
it is a very close approximation to the one margin condition an d is more powerful 
compared to the Fisher’s exact test, which is very conservative due to conditioning on 
both margins.42 
 
13.2 Analysis Plan 
The primary analysis will be assessment of the proportion of pa tients who achieve a 
PSA < 4ng/mL after 28 weeks of treatment in each arm.  The diff erence in proportions 
will be reported with the mid p-value method of the Fisher’s ex act test of the 2X2 table.  
The binomial proportions with the corresponding Wilson score 90 % binomial 
confidence intervals will also be reported by arm.  
 
Secondary endpoints include safety and tolerabili ty.  Frequency of adverse event types 
will be reported for each arm by attribution and grade.  Durati on of therapy, dose 
modifications and treatment delays will be reported to describe tolerability within each 
arm. 
 
The proportion of patients who achieve undetectable PSA (<0.2ng /mL), PSA response, 
and radiographic response will be reported by arm using methods described in the 
primary analysis.  Biochemical progression-free survival will b egin from treatment 
start until the event of biochemical (PSA) progression (section  11.2) or death, 
whichever occurs first.  Patie nts who do not have either event will be censored at their 
last known PSA date.  Clinical p rogression-free survival will b egin from treatment start 
until the event of clinical progression or death, whichever occ urs first.  Patients who 
do not have either event will be censored at the date of their last known clinical 
measure.  Biochemical PFS and clinical PFS will be described by  arm using Kaplan-
Meier methods and log-rank p-values will be reported. 
 
13.3 Correlative Endpoints Analyses 
  
 13.3.1  To determine whether cyclin D1, Cyclin D1B, Cyclin D3, p16, C DK4, 
Cyclin A or MCM7 levels in prebiopsy tissue as measured by IHC predict a subset 
of tumors responsive to palbociclib  or overall response rates, logistic models will 
be used.  Logistic models including one marker in each model an d response as the 
outcome will be performed.  The models for response rates will explore the one 
marker, treatment group, and the interaction of marker and trea tment group to 
determine if the marker is associated with response by palbocic lib.  Models of 
response rates with each marker without treatment group will be  explored if 
treatment associations are not found. Exploration using multipl e markers may be 
investigated using logistic modeling if there is indication tha t more than one marker 
75 
 is associated with response.  This is an exploratory aim for di scovery so multiple 
testing control will not be included. 
 
13.3.2 Concordance in RB status will be described between primary tumor, and 
metastases within patients using a generalized kappa.  Pairwise  concordance will 
be described with proportions, McN emar’s test and kappa statist ic. 
 
 13.3.3 To evaluate targeted sequenci ng and gene expression biomarkers  that predict 
response to palbociclib, patients will be class ified as respond ers or non-responders 
and individual biomarkers will be assessed for associations with response by Fisher’s exact tests or logistic  regression. A comparison of th e results for the subset 
of markers tested in 13.3.1 will be reported.  Similar approach es will be used with 
transcriptome/exome sequencing data.  13.3.4 The number of and heterogeneity  in circulating tumor cells at baseline, 
during treatment, and after treatment will be described by trea tment arm.  Analyses 
will be exploratory. Models may be used to explore baseline CTC s
 enumeration 
and molecular characteriza tion to predict response.   
 
   
76 
 REFERENCES 
 
 1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. C A Cancer J Clin 62:10-
29, 2012  2. Lytton B: Prostate cancer: a brief history and the discover y of hormonal ablation 
treatment. J Urol 165:1859-62, 2001  3. Sowery RD, So AI, Gleave ME:  Therapeutic options in advance d prostate cancer: 
present and future. Curr Urol Rep 8:53-9, 2007  4. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen 
deprivation in prostate c ancer. N Engl J Med 368:1314-25, 2013 
 5. Burkhart DL, Sage J: Cellular mechanisms of tumour suppress ion by the 
retinoblastoma gene. Nat  Rev Cancer 8:671-82, 2008 
 6. Knudsen ES, Knudsen KE: Tailoring to RB: tumour suppressor status and 
therapeutic response. N at Rev Cancer 8:714-24, 2008 
 7. Sharma A, Yeow WS, Ertel A, et al: The retinoblastoma tumor  suppressor controls 
androgen signaling and human prosta te cancer progr ession. J Cli n Invest 120:4478-92, 2010 
 8. Schiewer MJ, Augello MA, Knudsen KE: The AR dependent cell cycle: 
mechanisms and cancer relevance.  Mol Cell Endocrinol 352:34-45,  2012 
 9. Comstock CE, Augello MA, Goodwin JF, et al: Targeting cell cycle and hormone 
receptor pathways in cancer. Oncogene, 2013  10. Lim JT, Mansukhani M, Weinstein IB: Cyclin-dependent kinas e 6 associates with 
the androgen receptor and enhances its transcriptional activity  in prostate cancer cells. Proc Natl 
Acad Sci U S A 102:5156-61, 2005  11. Comstock C, Augello, MA, Goodwon, J, et al.: Targetting Cell Cycle and Hormone Receptor Pathways in Cancer. Oncogene:in press, 2013  12. Comstock CE, Augello MA, Schiewer MJ, et al: Cyclin D1 is a selective modifier 
of androgen-dependent signaling and androgen receptor function. J Biol Chem 286:8117-27, 2011  13. Flaherty KT, Lorusso PM, Demichele A, et al: Phase I, dose -escalation trial of the 
oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administ ered using a 21-day schedule in 
patients with advanced cancer . Clin Cancer Res 18:568-76, 2012 
 14. Finn R: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs le trozole alone for first-line treatment 
of ER+/HER2- advanced breast can cer (BC). San Antonio Breast Ca ncer Symposium, 2012 
 15. Barbieri CE, Baca SC, Lawrence MS, et al: Exome sequencing  identifies recurrent 
SPOP, FOXA1 and MED12 mutations i n prostate cancer. Nat Genet 4 4:685-9, 2012 
 16. Grasso CS, Wu YM, Robinson DR, et al: The mutational lands cape of lethal 
castration-resistant pros tate cancer. Nature 487:239-43, 2012 
 17. Tamboli P, Amin MB, Xu HJ, et al: Immunohistochemical expr ession of 
retinoblastoma and p53 tumor suppressor genes in prostatic intr aepithelial neopla sia: comparison 
with prostatic adenocarcinoma  and benign prostate. Mod Pathol 1 1:247-52, 1998 
 18. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-s pecific antigen value 
after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162 ). J Clin Oncol 24:3984-90, 
2006  19. Hussain M, Goldman B, Tangen C, et al: Prostate-specific a ntigen progression 
predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology 
Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Onco l 27:2450-6, 2009 
77 
  20. Bogina GS, Lunardi G, Marcolini L, et al: P16 but not reti noblastoma expression 
is related to clinical outcome  in no-special-type triple-negati ve breast carcinomas. Mod Pathol, 
2013 
 21. Kudahetti SC, Fisher G, Ambroisine L, et al: Immunohistoch emistry for p16, but 
not Rb or p21, is an independent predictor of prognosis in cons ervatively treated, clinically 
localised prostate can cer. Pathology 42:519-23, 2010 
 22. Berger MF, Lawrence MS, Demichelis F, et al: The genomic c omplexity of primary 
human prostate cancer. Nature 470:214-20, 2011  23. Crowley E, Di Nicolantonio F, Loupakis F, et al: Liquid biopsy: monitoring cancer-genetics in the blood. Nat  Rev Clin Oncol 10:472-84, 2013 
 24. Cho EH, Wendel M, Luttgen M , et al: Characterization of ci rculating tumor cell 
aggregates identified in patient s with epithelial tumors. Phys Biol 9:016001, 2012 
 25. Lazar DC, Cho EH, Luttgen MS, et al: Cytometric comparison s between circulating 
tumor cells from prostate cancer patients and the prostate-tumo r-derived LNCaP cell line. Phys 
Biol 9:016002, 2012  26. Marrinucci D, Bethel K, Kolatkar A, et al: Fluid biopsy in  patients with metastatic 
prostate, pancreatic and br east cancers. Phys Biol 9:016003, 2012 
 27. Nieva J, Wendel M, Luttgen MS, et al: High-definition imag ing of circulating 
tumor cells and associated cellular events in non-small cell lu ng cancer patients: a longitudinal 
analysis. Phys Biol 9:016004, 2012  28. Wendel M, Bazhenova L, Boshuizen R, et al: Fluid biopsy fo r circulating tumor 
cell identification in patients with early-and late-stage non-s mall cell lung cancer: a glimpse into 
lung cancer biology. Phys Biol 9:016005, 2012  29. Scher H, Landers, M, Jendrisak, A, et al.: Characterizatio n of Circulating Tumor 
Cells (CTCs) in metastatic Castration Resistant Prostate Cancer  (mCRPC) patients in First, Second 
& Third Line Systemic Therapies. Abstract presented at the 2014  ESMO meeting, Barcelona Spain  
 30. Bambury R, Landers, M, Louw, J, et al.: Characteristics of  de novo  resistance to 
Androgen Targeting Therapeutics (AR Tx) through Circulating Tum or Cells (CTCs) analysis in 
metastatic Castration Resistant Prostate Cancer (mCRPC) patient s.  . Abstract presented at the 
2014 ESMO meeting, Barcelona, Spain.   31. Schwartz GK, LoRusso PM, Dickson MA, et al: Phase I study of PD 0332991, a 
cyclin-dependent kinase inhibitor, administered in 3-week cycle s (Schedule 2/1). Br J Cancer 
104:1862-8, 2011  32. Goldhoff P, Clarke J, Smirnov I, et al: Clin ical stratific ation of glioblastoma based 
on alterations in retinoblastoma tumor suppressor protein (RB1)  and association with the proneural 
subtype. J Neuropathol Exp Neurol 71:83-9, 2012  33. Augello MA, Burd CJ, Birbe R, et al: Convergence of oncoge nic and hormone 
receptor pathways promotes metastatic phenotypes. J Clin Invest  123:493-508, 2013 
 34. Taylor BS, Schultz N, Hieronymus H, et al: Integrative gen omic profiling of human 
prostate cancer. Can cer Cell 18:11-22, 2010 
 35. Yu J, Mani RS, Cao Q, et al: An integrated network of andr ogen receptor, 
polycomb, and TMPRSS2-ER G gene fusions in prostate cancer progression. Cancer Cell 17:443-
54, 2010  36. Lonigro RJ, Grasso CS, Robinson DR, et al: Detection of so matic copy number 
alterations in cancer using targeted exome capture sequencing. Neoplasia 13:1019-25, 2011 
 37. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al: Rearrang ements of the RAF 
kinase pathway in prostate cancer, gastric cancer and melanoma.  Nat Med 16:793-8, 2010 
78 
  38. Roychowdhury S, Iyer MK, Robinson DR, et al: Personalized oncology through 
integrative high-throughput se quencing: a pilot study. Sci Tran sl Med 3:111ra121, 2011 
 39. Wang XS, Shankar S, Dhanasekaran SM, et al: Characterizati on of KRAS 
Rearrangements in Metastatic Pr ostate Cancer. C ancer Discov 1:3 5-43, 2011 
 40. Cheng HH, Mitchell PS, Kroh EM, et al: Circulating microRN A profiling identifies 
a subset of metastatic prostate cancer patients with evidence o f cancer-associated hypoxia. PLoS 
One 8:e69239, 2013 
 41. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response  evaluation criteria in 
solid tumours: revised RECIST guideline (version 1.1). Eur J Ca ncer 45:228-47, 2009 
 42. Lydersen S, Fagerland MW, Laake P: Recommended tests for a ssociation in 2 x 2 
tables. Stat Med 28:1159-75, 2009     
79 
 APPENDIX A 
 
 
Performance Status Criteria 
 
ECOG Performance Status Scale  Karnofsky Performance Scale 
Grade Descriptions Percent Description 
0 Normal activity.  Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work. 
2 I n  b e d  < 5 0 %  o f  t h e  t i m e .   Ambulatory and capable of all self-care, but unable to carry out any work activities.  Up and about more than 50% of waking hours. 60 Requires occasional assistance, but is able to care for most of his/her needs. 
50 Requires considerable assistance and frequent medical care. 
3 In bed >50% of the time.  Capable of only limited self-care, confined to bed or chair m ore than 50% of waking hours. 40 Disabled, requires special care and assistance. 
30 Severely disabled, hospitalization indicated.  Death not imminent. 
4 100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair. 20 Very sick, hospitalization indicated. Death not imminent. 
10 Moribund, fatal processes progressing rapidly. 
5 Dead. 0 Dead. 
     
80 
 APPENDIX B 
 
Standard Operating Procedures for CT-guided Biopsy of Metastati c Prostate Cancer 
Lesion in Bone 
 
Patients will be scheduled f or a CT-guided biopsy of a bone or soft tissue abnormality consistent 
with prostate metastasis.  The s ite of biopsy will be determine d after review of available 
radiographs, CT, MRI, and/or bone s can (where applicable).  The  decision regarding which 
metastatic lesion to biopsy s hould depend on three main factors : 
1) Size of lesion (with preference towards the largest lesion) 
2) Safety (with obvious preference towards least ri sk to the patient) 
3) For bone lesions, the intensit y of lesion activity on bone scan  (with preference 
towards the most intense activity) 
Verbal and written informed consen t will be obtained after discussion of risks (bleeding, 
infection, soft tissue and bone i njury, inconclusive biopsy res ults) of the procedure.  Standard 
laboratory tests to assess coagulation and bleeding will also b e completed prior to the procedure.  
Conscious sedation will be used a s necessary using intravenous Fentanyl and Midazolam with 
appropriate nursing support. In ord er to ensure adequate tumor sample as long as it is deemed 
safe and based on accessibility, ta rget lesion size, specimen integrity, specimen appearance, 
intra-procedural b leeding, tumor biopsy should attempt to obtai n   2-8 bone biopsy samples in 
addition to possible bone marrow aspirate, to be determined at the time of biopsy. 
  The patient will be initially sca nned with a clinically-availab le multislice CT scanner for the 
purpose of biopsy planning.  Biopsies will be performed using sterile technique and lidocaine local anesthetic. For bone lesions , a clinically-available 11-t o-14 gauge bone cutting needle, with 
or without a co-axial troc ar, will be used to obtain  two to eight  biopsy samples of the selected 
lesion.  Options for obtaining multiple samples of the biopsy c an include: 
a) Sequential advancement of needle  passes through a fixed trocar, 
such that each needle pass progr esses more deeply into the bone 
lesion 
b) Re-insertion and re-direction of the needle and/or trocar through another region of the bone lesion  
c) Aspiration of the lesion will be  attempted in conjunction with 
biopsy, by attaching a 20 cc steril e syringe to the cannula of the 
biopsy needle and aspirating int o this syringe, with repeat 
aspirations as needed. 
 At the completion of the procedure, CT imaging will be repeated  to assess for immediate 
complications.  The patient wi ll be observed for 2 – 4 hours before discharge. 
  
  
81 
 APPENDIX C 
 
Standard Operating Procedures for CT-guided Biopsy of Metastati c Prostate Cancer 
Lesion in Soft Tissue 
 
The patient’s imaging will be reviewed and all soft tissue or n odal lesions deemed suspicious for 
metastasis will be considered. A target for sampling will be se lected based on: 1) perceived 
percutaneous access with respect  to safety and technical feasibility, and 2) suspected likelihood 
of obtaining malignant tissue. In the cases where both bone and  soft tissue lesions are safely 
accessible and have high likelihood s of containing malignant tissue, it would be preferable to 
biopsy the soft tissue lesion.  
 
 For lymph nodes or soft tissue lesions a CT scan will be utiliz ed.  An ultrasound may be 
utilized, provided that the target lymph node or soft tissue ma ss is visible and accessible. 
    
 In order to ensure adequate tum or sample as long as it is deeme d safe and based on 
accessibility, target lesion size , specimen integrity, specimen  appearance, intra-
procedural bleeding, tumor biopsy should attempt to obtain: 
o  at least 6 cores if obtaini ng a 1-cm-long 18-gauge core specim en.   
or 
o at least 4 cores if obtaining a 2-cm-long 18-gauge core specime n.  The needle 
should be directed into the center of the lesion.  
 Options for obtaining multiple samples include similar principl es as described for bone lesions, 
including sequential advancemen t through the lesion, re-insertion/re-direction, or aspiration 
where appropriate.  Mitigating factors may include but are not limited to: 1) safet y of obtaining multiple core 
specimens, 2) friability of the  core specimens on visual inspection, 3) target size, 4) perceived 
likelihood of obtaining additional diagnostic tissue by continu ed sampling. After biopsy is 
performed, the biopsy would be snap frozen, as described in App endix E.  No aspirate will be 
performed for soft tissue biopsies. 
    
82 
 Appendix D: Standard Operating P rocedure (SOP) for Handling Sam ples  
 
1.0 PURPOSE  
To standardize the method for ha ndling frozen needle tumor biop sies, to optimize specimen use 
for molecular analyses. 
 
2.0 MATERIALS AND EQUIPMENT REQUIRED  
 
2.1 Sample kit containing: 
Dual sample kit will be sent t o each enrolling site immediately  following patient 
registration 
A) Cell Free DNA 2 tubes B) Sheet for reco rding biopsy details 
This sample kit will be sent t o each enrolling site immediately  following patient 
registration. 
 
2.2 Other materials which will be s ent to each enrolling site at t he initiation of the clinical trial 
(to be kept for use over serial cases):  
a) One box Tissue Tek™ cryomolds 
b) Large bottle of Tissue Tek™ OCT 
c) Blue Pads, Markers  
d) Sterile tweezers  
e) Shipping labels 
f) A supply of additional Cell-Free DNA tubes  
g) Boxes for shipment of Cell-Free DNA samples (see Appendix F) 
 
2.3 Materials that will be provided by the enrolling site: 
a) Dry ice  
b) -80°C freezer (particularly i n the case of Friday biopsies) 
 
3.0 OPERATING PROCEDURES  
 
3.1 At least 24 hours prior to the biop sy, the research coordinator is to notify the institutional 
research team involved in this protocol, of the scheduled sample collections.  A laboratory 
technician should pick up the sam ple kit (see 2.1 above), and p repare cryomolds prior to the 
biopsy, by labeling them, using the  provided alcohol-proof mark er, with the following 
information:               Clinical protocol number              Specimen ID               Biopsy time and Date       The research coordinator and the laboratory technician should also confirm, on the day prior to biopsy, the availability of materials needed for handling the b iopsies, as specified in Section 2 
above.  3.2 The laboratory technician should  arrive at the biopsy collectio n site at least 15 min ahead of 
the scheduled biopsy to allow sufficient time to set up laborat ory supplies and ensure rapid 
83 
 transport of specimens to the laboratory after collection.  He or she should also re-confirm, at 
that time, the availability of  all specimens from Section 2.  H e should also, immediately before 
the biopsy, fill the insulated bucke t with dry ice and isopentane. 
 
3.3  Immediately after the biopsy is performed, the freshly collected specimen should be placed in the cryomold.  A single drop  of Tissue Tek™ OCT should be p laced on the specimen, and the 
sterile tweezers should be used to gently hold one end of the f reshly collected needle biopsy and 
to push the biopsy to the bottom of  the cryomold cassette with forceps.  Make sure biopsy is as 
flat as possible. The cryomol d should then be filled with OCT, and the cryomold should be 
immediately placed in direct contact with the dry ice/isopentan e cocktail until the bottom of the 
OCT freezes and turns white.  Only the bottom of the cryomold s hould contact the dry 
ice/isopentane--none of the dry ice/isopentane should spill ins ide the cryomold itself and contact 
the specimen.   
This process can be repeated using separate cryomold cassettes for separate biopsy samples. 3.4 Once frozen, place cryomolds on dry ice for transport.  The use d isopentane should be 
poured back into its bot tle using funnel.     
3.5 For bone lesions, an aspirate  of the site of bone biopsy may b e performed, as described in 
Section C, using a 20 cc sterile syr inge.  The contents of this syringe (clotted a spirate) should be 
transferred into a 1.7 mL eppendorf tube.  Several drops of Tis sue Tek™ OCT should be added 
to the tube, such that the clot ted aspirate is covered by OCT.  The eppendorf tube should then be 
closed, and placed on dry ice for snap freezing. 3.6 The cryopreserved biopsy and aspirate specimen(s) should be sto red at -80°C until shipment.  
Ideally, shipment should occur on the same day as the biopsy, u nless the biopsy occurs on a 
Friday, in which case the speci men should be preserved at -80°C  until shipment on the following 
Monday. 
  
4. Quality Assurance Process 
After completion of each biopsy, t he following information shou ld be recorded on the 
information sheet shipped with each sample kit: 
Biopsy collection 
Date:  
Specimen ID:  Time guide needle placement confirmed:  Needle Type:  Needle diameter: gauge; and length: cm  Time biopsy needle introduced:  Time biopsy snap-frozen on dry ice:  Number of specimens: Time aspirate performed (for bone lesions): Time aspirate snap-frozen on dry ice: Date/time of biopsy specimen(s) ( and aspirate specimens, if applicable) placed at -80°C:  
Date/time of biopsy specimen(s) ( and aspirate specimens, if applicable) shipped:  
Notes, including any deviations from the standard operating pro cedure:  
  
84 
 Appendix E: Standard Operating P rocedure for Shipment of non-CT C Clinical Samples 
 
I.  Preparing for Shipment 
A. Send an e-mail to Siddiqui@med.umich.edu   prior to shipping to a dvise recipient of 
scheduled shipping time.  
B. Generate a shipping list recording the number of samples bei ng shipped, type of 
sample (frozen biopsy, blood, or a rchived formalin-fixed biopsy ), and clinical protocol 
number of the patient C.  Make sure that the following packing materials are availabl e: 
 Cardboard shipping box with Styrofoam insert.  
--Shipper Boxes 13.38L x 9.25W x 6 in.D;  Outside Dimensions: 15.5L x 11.5W x 8 in.H;  Wall Thickness: 1 in . Fischer Scientific Catal og # 03-
528-27 
 Dry ice (amount varies depending on size of Styrofoam insert; u sually about 
15 kg’s) 
 6 in x 6 in cardboard specimen box, with fiberboard box divider s- holds 81, 
16mm vials  
--Revco Fiberboard Storage Boxes, 12/PAK 
--Revco Fiberboard Box Dividers , Holds 81 16mm vials, 12/PAK 
Fischer Scientific Cat alog # 11-678-24A, 13-989-218 (resp.) 
 Plastic bag (to go over the cardboa rd box –in case of leakage) 
 Absorbent strip (to go inside th e plastic bag that the boxes ar e in; can soak up to 
250 cc of liquid) 
--Absorbent Strips 250/Cs 
--Fischer Scientific Catalog # NC9193000 
 UN 3373 label (2 in x 2 in)  
--Labelmaster UN3373 Labels > 2W x 2.75 In. L --Labels; Biological Substance; 2W x 2.75 In. L; Paper; 500/RL 
Fischer Scientific Catalog # NC9493045 
 Dry Ice Label with designate d UN 1845 diamond (can also be orde red from 
Fischer Scientific) 
--5 1/2 x 5 1/2 in.; complies wi th DOT (49 CFR 173.217) and IAT A 
(Packing Instructions 904)   
--Fischer Scientific Catalog #22-130-065  
 Packing tape 
 II.  Packaging the specimens 
1. Pull sample tubes from temporary storage freezers and place in dry ice, make sure the 
labels are securely placed on the  tube and tubes properly label ed and easy to read. 
2. Ensure that caps are tightly secured and place in 6 in x 6 in c ardboard specimen box 
(which should be kept on dry i ce during this transfer). 
3. Be sure to check off EACH specimen being shipped  a nd verify the contents of the 
package match the shipping list 
4. Label the top of the cardboar d specimen box with number of samp les; clinical 
protocol/specimen number, and con tact information of sender, as  well as contact of 
receiver. 
85 
 5. Cover the specimen box, and either t ape the sides down or place a rubber band around 
the box, to ensure that the cover will not come off. 
6. Place inside the plastic Ziploc ba g with the absorbent strip an d seal. Keep on dry ice 
until ready to transfer to the larger shipping box. (can fit tw o of these specimen boxes 
in a shipper box that is t he designated size above) 
7. Fill the shipper box about half way with dry ice (about 1-2 inc hes in height) and place 
the specimen box inside with shipper. 
8. Add more dry ice to cover the specimen boxes. (about 1 or 2 inc hes in height again 
and 1-2 inches on the sides the boxes as well).  Note: there should be sufficient dry 
ice to maintain the samples  at -20°C for at least 72 h. 
9. DO NOT place dry ice inside the  specimen boxes or inside the pl astic bag. 
10. Close the Styrofoam box, and tape the packing list to the top. DO NOT seal the 
Styrofoam box with tape.  
11. Ship the specimens with a copy of  the shipping list and the completed quality 
assurance record (see Appendix D ) for all specimens. Retain copies of the completed 
shipping list and quality assura nce record in your records. 
12. Seal the shipping box by taping th e flaps of the insulated box along the top edges. 
13. At this point, you should check tha t your final packaging consi sts of three 
components (triple packaging): 
 (a) a primary receptacles (the specimen tubes)  
 ( b )  a secondary packaging (6 in x 6 in cardboard specimen box) 
 ( c )  a rigid outer packaging (la rger cardboard shipping box) 
14. Should you decide to use alternative  packaging materials instea d of those listed 
above, please note the following requirements: 
The primary receptacles must be packed in secondary packaging i n such a way 
that, under normal conditions of transport, they cannot break, be punctured or leak 
their contents into the secondary packaging. Secondary packagin gs must be 
secured in outer packaging with suitable cushioning material. Any leakage of the 
contents must not compromise th e integrity of the cushioning ma terial or of the 
outer packaging. The primary container (i.e. test tube) must be leak proof, as should the secondary container. T he outer packaging (tertiary c ontainer) does not 
have to be leak proof.  Packaging mus t comply with the IATA packing 
instructions 650 which are summa rized below; for further questi ons, please refer 
to the IATA website: http://www.iata.org/SiteCollecti onDocuments/DGR51_PI650_EN.pdf 
 III.  Labelling and se nding the shipping box 
A. Fill out the black and white dry ice label to reflect the we ight of the dry ice in the box, 
note 2lbs= 1kg. Place completed black and white dry ice label o n the shipping box 
B. All shipping boxes must be affixed with two labels: 
“DIAGNOSTIC SPECIMENS PACKED IN COMPLIANCE WITH IATA PACKING INSTRUCTION 650” 
and 
“UN 3373 Biological Substance Category B”  
  
86 
 C. Complete the air bill online and attach packing labels to the outside of the shipper. 
Schedule a pick up time and ship overnight to: 
Javed Siddiqui, MS, MT(ASCP, CLsp (MB)) 
Michigan Center for Translational Pathology Room 1138  2900 Huron Parkway Suite 100 Ann Arbor, MI 48105 Phone: (734) 232-0829 Fax: (734) 232-0805 siddiqui@med.umich.edu 
D. All shipping boxes are require d to ship out Priority Overnig ht (or another comparable 
shipping service that results i n delivery by 10:30 A M the follo wing day). 
E. Biopsies on Monday through Thur sday should be shipped on the same day as the 
biopsy.  Biopsies on Friday should be stored at -80 degrees Celsius until the following Monday, and then should be shipped via Priority Overnight (or a comparable service).   
F.  The sender would need to com plete an "air waybill" form 
G.  All diagnostic or investigational specimens shipped on this  trial should be classified 
as “Diagnostic Specimens” not “Infectious Substances” when ship ping via a standard 
carrier.  (i.e. UPS, FED-EX, DHL /AIRBORNE). Diagnostic Specimen s DO NOT 
require a Shipper’s Declarati on of Dangerous Goods form.  
 
IV.  Questions 
For any questions regarding shipp ing, please contact Javed Sidd iqui at 
siddiqui@med.umich.edu or phone: (734) 232-0829. 
  
87 
  
 
  

88 
  
  

89 
 Appendix G  
PATIENT’S MEDICATION DIARY 
 
Today’s date  _____________________     Agent: Palbociclib  
Patient Name _____________________(initials acceptable)    Patient Study ID  __________________________ 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each cycle of treatment. 
2. You will take Palbociclib  
           Dose:                                   ___75 mg capsules  
                                ___ 100 mg capsules 
                                ___ 125 mg capsules 
 
          Take Palbociclib daily, days 1-21. Take with food.   Do not crush, break, or chew it. 
3. Record the date, the number of tablets of each size of table t that you took, and when you took them.   
4. If you have any comments or notice any side effects, please record them in the Comments column.   
5. Please bring this form, bottles and extra tablets  when you return for  each appointment. 
6.      Please record missed or skipped doses.  Do not share yo ur study drug supply, and wash yo ur hands after touching the pi lls
 
 
Day  
Date Time of Dose # of capsules 
taken  Comments  
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
 
Patient’s signature____________________________________________ _____________________________ 
 
 
***FOR CLINIC STAFF USE ONLY *** 
STUDY STAFF 
SIGNATURE:  # of capsules dispensed to 
patient:  
DATE:  # of capsules returned:  
  
90 
 Appendix H  
PATIENT’S MEDICATION DIARY 
 
Today’s date  _____________________     Agent: Bicalutamide  
Patient Name _____________________(initials acceptable)    Patient Study ID  __________________________ 
INSTRUCTIONS TO THE PATIENT: 
1. Complete one form for each cycle of treatment. 
2. You will take Bicalutamide  
           Dose:  50mg           Take Bicalutamide daily every day of the month.   Do not crush, break, or chew it. 
3. Record the date and when you took it.   
4. If you have any comments or notice any side effects, please record them in the Comments column.   
5. Please bring this form, bottles and extra tablets  when you return for  each appointment. 
6.      Please record missed or skipped doses.  Do not share yo ur study drug supply, and wash yo ur hands after touching the pi lls
 
 
Day  
Date Time of dose  # of tablets taken Comments  
 
1     
2     
3     
4     
5     
6     
7     
8     
9     
10     
11     
12     
13     
14     
15     
16     
17     
18     
19     
20     
21     
22     
23     
24     
25     
26     
27     
28     
 
 
Patient’s signature____________________________________________ _____________________________ 
 
STUDY STAFF 
SIGNATURE:  
DATE:  
 